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ABSTRACT
Monoclonal antibody (MAb) production via the growth of
ascitic tumors in mice has been the time-honored technique
for producing small scale, research laboratory quantities of
MAbs. There are many disadvantages associated with MAb
production in murine ascites, including animal welfare
concerns. Small scale, commercially available, hollow fiber
bioreactor systems, which appear to have advantages over
other in vitro cell culture techniques, have recently been
introduced. To the author's knowledge, these bioreactor
systems have not been independently evaluated as a potential
alternative to the in vivo production of MAbs in murine
ascites. The first objective of this study was to
characterize the clinicopathologic changes in mice associated
with the in vivo production of MAbs. Five different
hybridoma cell lines were grown in groups of 20 mice. Mice
were primed with 0.5 ml pristane intraperitoneally 14 days
prior to inoculation of 1 x 106 hybridoma cells. Abdominal
paracentesis was performed a maximum of 3 times for
collection of ascites from each mouse; ascites volumes were
recorded. Clinical observations, body weight measurements,
and postmortem examinations were performed. Incidence and
severity of clinical abnormalities increased with time.
Disseminated intraabdominal seeding of tumor and/or solid
tumor masses were observed at postmortem examination. The
second objective of the study was to compare MAb production
in mice versus hollow fiber bioreactor systems to determine
the feasibility of these systems as potential alternatives to
the use of mice. Three hybridoma cell lines were grown in
each of three different commercially available hollow fiber
bioreactor systems and in groups of 20 mice. Bioreactors
were harvested 3 times weekly for 65 days and were monitored
by cell counts, cell viability and media glucose consumption.
Time and materials logs were maintained. Time spent in labor
and materials costs were greater for the bioreactors than the
mice. The mean antibody concentration, as determined by
ELISAs, in mouse ascites versus the range of mean
concentrations for the 3 bioreactor systems for each cell
line were as follows: cell line 2B11, 4.22 mg/ml vs. 0.71 to
1.31 mg/ml; cell line 3C9, 4.07 mg/ml vs. 2.16 to 4.45 mg/ml;
and cell line RMK, 8.37 mg/ml vs. 2.30 to 11.08 mg/ml. The
total quantity of antibody produced in 20 mice versus the
mean production for 3 bioreactors in 65 days was as follows:
cell line 2B11, 454.50 mg vs. 168.35 mg; cell line 3C9,
445.57 mg vs. 564.52 mg; and cell line RMK, 996.64 mg vs.
1023.06 mg. Significant clinicopathologic changes in mice
were associated with MAb production in ascites. Although
time and materials costs were greater for the bioreactors,
these results suggest that hollow fiber bioreactor systems
merit further investigation as potentially viable
alternatives to the use of mice for MAb production.
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SECTION 1 : INTRODUCTION
Mice which have been injected intraperitoneally with an
ascitogenic priming agent, followed by inoculation with
hybridoma cells, produce ascites which contains high
concentration of monoclonal antibody secreted by the
hybridoma cells. This fluid can subsequently be aspirated
from the abdominal cavity and then processed and purified
to obtain the antibody. This has been the time-honored
technique for producing small scale, research laboratory
quantities of monoclonal antibodies.
From personal observation of mice used for ascites
production, and scientific reports, it was apparent that
significant morbidity and mortality may be associated with
this procedure. There is considerable information in the
literature regarding antibody production parameters, but
relatively little information which addresses the
clinicopathologic changes in mice associated with this
procedure.
In vitro methods are available for growth of hybridoma
cells, but there are significant disadvantages associated
with these techniques which have discouraged their
widespread use.
As veterinarians and others with concerns for the
welfare and humane care of animals used in research, we
sought to characterize the clinicopathologic changes in
mice associated with ascites production and identify a
viable in vitro alternative to the use of mice for small
scale production of monoclonal antibodies.
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BACKGROUND AND SIGNIFICANCE
History of Antibody Production in Murine Ascites
In 1957, Munoz first described a technique for
obtaining antibodies from mouse ascitic fluid. He
demonstrated that intraperitoneal injection of complete
Freund's adjuvant-antigen mixtures in mice resulted in the
production of large volumes of ascites which contained high
concentrations of antigen-specific antibody (57). In 1961,
Lieberman et al reported that ascites was produced
following intraperitoneal injection of incomplete Freund's
adjuvant and heat-killed Staphylococcus aureus in mice
preimmunized subcutaneously with horse serum and incomplete
Freund's adjuvant. Seventeen strains of mice were
evaluated in that study. Strain variation and individual
variation in ascites production was demonstrated, with CAF1
mice producing relatively large volumes of ascites.
BALB/cAnN mice which received incomplete Freund's adjuvant
alone also produced ascites, and 10 of 19 animals that
survived beyond 6 months developed plasma cell tumors (58).
Following observations of plasmacytoma induction by
intraperitoneal injection of mineral oil into BALB/c mice,
Anderson and Potter, in 1969, identified a component of
mineral oil, pristane (2,6,10,14-tetramethylpentadecane), a
saturated branched-chain hydrocarbon, as a potent inducer
of plasmacytomas in BALB/c mice following 3 intraperitoneal
9
SECTION 2:
injections. Nineteen of 30 animals developed tumors within
one year. One of these plasmacytomas was found to produce
monoclonal antibody (55). Cells obtained from a
plasmacytoma induced by intraperitoneal injection of
mineral oil into a BALB/c mouse were referred to as MOPC
for mineral oil plasmacytoma, and continuous plasmacytoma
cell lines subsequently derived and established from this
tumor are currently in use as fusion partners for
production of hybridomas (59). In 1972, Potter et al
demonstrated that plamacytomas could be propagated as
ascites tumors in mice which had been pretreated with an
intraperitoneal injection of mineral oil (60).
In 1976, Khler and Milstein first described fusion of
BALB/c mouse plasmacytoma cells and spleen cells from
immunized mice, with subsequent selection to produce a
hybridoma cell line secreting antibody of predefined
specificity (1). Subcutaneous injection of these hybridoma
cells into BALB/c mice lead to solid tumor formation and
intraperitoneal injection resulted in the development of
ascites tumors. The sera of these animals was found to
contain specific antibody, and they reported that these
cells could be grown in vitro to provide antibody (1,2).
Monoclonal Antibody Production in Murine Ascites
There have been many developments in the production and
application of monoclonal antibodies since K6hler and
Milstein first described the technique for producing
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hybridoma cells which secreted monoclonal antibodies (1,2).
Ascites production following intraperitoneal inoculation of
hybridoma cells into pristane primed, histocompatible mice
has been the time-honored technique for producing
monoclonal antibodies (3,4,5). Ascitic tumors form in the
abdominal cavity of the mouse, and the antibody-rich
ascitic fluid is harvested by paracentesis.
Although an extremely useful technique, there are a
number of disadvantages associated with production of
monoclonal antibodies via the induction of ascitic tumors
in mice which have been cited. Many of the criticisms
which have been raised reflect humane concerns regarding
the potential for different aspects of this procedure to
induce pain or distress in the animals. These concerns are
magnified by the large number of mice used in this process.
Pristane, a hydrocarbon derived from mineral oil, is
commonly used to prime the peritoneal cavity prior to
hybridoma cell inoculation. Pristane is thought to act by
inducing granulomatous inflammation and interfering with
peritoneal lymphatic drainage (6) thus increasing the
volume of ascites produced. Injection of large volumes of
pristane intraperitoneally in mice has been associated with
weight loss, hunched appearance, and inactivity (7). The
exact volume of pristane administered was not indicated,
however. Peritonitis is known to cause abdominal pain in
animals (8).
According to the material safety data sheet, pristane
11
can cause severe irritation if it comes into contact with
the eyes, mucous membranes, skin, respiratory, or
gastrointestinal tract, and it is classified as a
tumorigenic agent, therefore requiring that appropriate
precautions be taken when handling the agent.
Inoculation of large numbers of hybridoma cells has
been shown to cause significant mortality in mice. In a
study reported by Chandler, 3 groups of 20 pristane primed
BALB/c mice were inoculated with 1 x10 5, 5 x 105, or 2 x 106
hybridoma cells, respectively. In the group which received
2 x 106 cells, 11 of 20 mice died before the second
abdominal tap. Chandler also reported that for most cell
lines, even when employing a standard inoculum of 5 x 105
cells/mouse, only 10-25% of the animals usually survive to
the third abdominal tap (4).
In humans, mild ascites is often asymptomatic and
generally not painful, but large amounts of ascites can
cause severe abdominal discomfort, respiratory distress,
anorexia, nausea, heartburn, and difficulty in ambulation
(9,10). Ascites also causes abdominal pain in animals (8).
Increased abdominal pressure created by ascites results in
cranial displacement of the diaphragm which decreases
ventilatory capacity and compromises gas exchange.
Respiratory distress may be exhibited clinically as
tachypnea or dyspnea. Additionally, increased abdominal
pressure can produce venous stasis in the abdomen, decrease
arterial blood pressure, and decrease renal blood flow (8).
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The potential for abdominal distention and pain induced
by the increasing abdominal tumor mass has also been
addressed (5,11,12). Abdominal carcinomatosis in humans
has been reported to be painful (9). While abdominal
pressure may be at least temporarily reduced by removal of
ascitic fluid, the tumor remains and continues to increase
in mass over time. Abdominal carcinomatosis in humans and
animals is generally associated with progressive weakness,
debilitation, and cachexia (8,9).
In both human and veterinary medicine, it is not
generally recommended that ascites fluid be removed by
paracentesis. Potential complications associated with
rapid or repeated removal of ascites include hypovolemia
from compensatory fluid shifts and hypoalbuminemia (13,14).
McGuill and Rowan have suggested that the possibility of
physiologic stress due to hypovolemia as well as the
possibility of stress induced by the collection procedure
should be considered with regard to repeated abdominal
paracentesis in mice (5). The number of abdominal taps
permitted for collection of ascites from mice is now
limited to 1 to 3 taps by most Institutional Animal Care
and Use Committees.
As a result of the animal welfare concerns which have
been raised, several European countries have established
guidelines or regulations which restrict or prohibit
ascites production in rodents. The United Kingdom
Coordinating Committee on Cancer Research (UKCCCR)
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"Guidelines for the Welfare of Animals in Experimental
Neoplasia" states that predictable death is generally an
unacceptable end point, that the volume of ascitic fluid
should not become excessive or cause gross abdominal
distention, and that solid tumor growth and cachexia should
not become clinically significant. The guidelines state
that ascitic volumes should not usually exceed 20% of
normal body weight, that ascites should normally be drained
only once, and that general anesthetics should be employed
during paracentesis (12).
The Switzerland "Rules for the Judgement of Approval
Requests for Animal Experiments for the Production of
Monoclonal Antibodies" states that the ascites procedure is
incompatible with the animal protection law, the
Netherlands "Code of Practice for the Production of
Monoclonal Antibodies" states that the in vitro method will
be preferred to the in vivo method, and the German Federal
Health Office in Berlin has accepted the UKCCCR guidelines
(11).
Although murine monoclonal antibodies can be produced
in high concentrations by growth of cells as ascitic tumors
in histocompatible mice, similar attempts to grow
heterohybridomas and xenogenic hybridomas have been much
less successful (15,16,17,18,19,20). Methods such as X-ray
irradiation of mice (16,17); treatment with
immunosuppressive drugs such as antilymphocyte globulin,
methotrexate, cyclophosphamide (16) or hydrocortisone (17);
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prior subcutaneous adaptation of hybridoma cells (15); and
the use of T-cell deficient (15,16,18) or T-cell and B-cell
deficient SCID mice (19) have been employed in attempts to
improve production. Even when utilizing one or more than
one of these methods simultaneously, the efficiency of take
for human hybridomas in mice may be as low as 50% (20).
The additional expense of purchasing and maintaining
aseptic housing and handling practices for immunodeficient
mice impacts production costs.
Other concerns regarding antibody raised in vivo in
murine ascites, particularly in relation to products
intended for human clinical use, include the potential for
contamination by murine adventitious agents, endogenous
murine immunoglobulin and other murine proteins and nucleic
acids, endotoxin, and residual pristane (21). The
potential presence of adventitious agents and endogenous
immunoglobulin impose additional difficulties in
purification and quality control testing of the product
(22). It should be noted, however that all of these
concerns are not unique to antibody production in mouse
ascites; for example, if the hybridoma itself is of animal
cell origin there are concerns regarding adventitious
agents regardless of the method of production (23). Cell
culture media additives such as serum and antibiotics pose
similar concerns for contamination of the product (22).
Using immunocytochemical techniques, Spicer et al
recently identified contaminants in several murine ascites-
15
derived monoclonal antibodies which demonstrated binding to
Golgi zones on epithelial cells that was unrelated to the
antigenic specificity of the antibody. Hybridoma cell
culture supernatants examined from two of the hybridomas
showed no Golgi staining. Additional studies suggested
that the ligand reacting with the Golgi complex could also
be found in some mouse sera and was related to the presence
of mouse anti-blood type A antibody. Based on these
findings, the authors warn against making the assumption
that ascites-derived monoclonal antibodies will always
demonstrate absolute antigen specificity in
immunocytochemical staining (24). These findings point to
possible sources of lot to lot variability in murine
ascites-derived monoclonal antibodies.
Truitt et al reported gross morphological changes and
changes in the DNA content of human/human hybridoma SA13
ascites passaged cells from nude mice by comparison to
cells grown only in culture. Ascites passaged cells had
greater aneuploid DNA level, and the authors hypothesized
that the hybridoma cells may have taken up mouse DNA or
over-replicated human chromosomal material. They suggested
that this could be an indication of genetic instability
resulting from the introduction of cultured cells into the
foreign environment of the mouse peritoneal cavity (15).
To study the possible effects of pristane on the DNA of
murine hybridoma cells, Garrett et al, using flow
cytometric profiles of propidium iodide-stained hybridoma
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cells obtained from ascites 1 month post pristane and 2
weeks post hybridoma cell inoculation, showed decreased
fluorescent intensities compared to the parent hybridoma
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pharmacokinetics (29).
All of the findings cited thus far substantiate the
need for alternatives to the use of mice for monoclonal
antibody production.
History and Applications of Monoclonal Antibodies
Monoclonal antibodies are valuable tools used in a
variety of clinical and research applications.
Historically, in the mid to late 1970's most monoclonal
antibodies were used in research, and quantities of 100 mg
were considered to be very large. Mouse ascites and
conventional suspension culture were the production systems
of choice. By the early 1980's, use of monoclonal
antibodies in immunopurification of biologicals and in in
vitro diagnostic kits dramatically increased the need for
large quantities of antibodies. Beginning in the mid
1980's, monoclonal antibodies were evaluated for in vivo
use for diagnostic imaging and therapeutic applications.
These applications further increased the need for large
scale production of monoclonal antibodies in the range of
100s of kilograms or more per product, and encouraged
development of novel in vitro culture methodologies (30).
Current applications for monoclonal antibodies include
in vitro affinity purification, and immunodiagnostics for
tissue typing, therapeutic drug monitoring, and
quantitation of hormones, growth factors, immunoglobulins,
enzymes, and microorganisms. Monoclonal antibodies are
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used in vivo as diagnostic imaging agents, and monoclonal
antibody-toxin conjugates are being used for cancer therapy
(30,31). Monoclonal antibodies are also being used as
catalysts and templates for organic chemical reactions
(31).
Monoclonal Antibody Production In Vitro
In vitro cell culture systems are now widely used for
large scale production of monoclonal antibodies (26,30,32).
In the research laboratory, small quantities, i.e.
milligram quantities, of many different monoclonal
antibodies are generally required. Disadvantages
associated with many in vitro techniques have made them
unsuitable for widespread use as alternatives to murine
ascites for small scale monoclonal antibody production.
There are many advantages of monoclonal antibody
production in mice against which in vitro technologies must
compete. Production is rapid in mice with ascites often
developing within 2-10 days following hybridoma inoculation
(33). Mice can support the growth of most cell lines (4)
and minimal materials and technical expertise are required.
Antibody in mouse ascites is highly concentrated, ranging
from approximately 0.5-20 mg/ml, and the concentrations in
cell culture supernatants have been reported to be between
one-hundreth and two-thousandths of the concentration
achieved in mice (11). Because of low antibody
concentrations in cell culture supernatants, large volumes
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(34). Antibody production in mice has also been
to be less costly than in vitro production (35).
iety of in vitro cell culture techniques have been
to produce monoclonal antibodies from hybridoma
a laboratory scale. The methods commonly used
tationary cultures in T-flasks, and suspension
in roller bottles and spinner flasks, all of which
ally handled as batch cultures (11,20,22). Other
s include growth of cells in dialysis tubing (36),
cillating bubble dialysis chambers (34),
psulation of cells in gelled sodium alginate
oated with a biopolymer to form a semi-permeable
membrane (30,37), and entrapment of cells in agarose beads
(38). Laboratory scale stirred tank reactors (39,40),
fermentors (41), and ceramic-matrix bioreactors (42) have
also been used Advantages and disadvantages have been
cited for all these production systems, but one
disadvantage was consistent; the antibody product obtained
from these in vitro systems was far less concentrated than
that produced in mouse ascites.
Hollow Fiber Bioreactors
Recently, commercially available, laboratory scale
hollow fiber bioreactor systems have been introduced.
Initial investigations of these systems suggested that they
had advantages over other in vitro systems and might
20
provide an economically feasible alternative to mice for
small scale production of monoclonal antibodies.
The hollow fiber/artificial capillary cell culture
system was first introduced by Dr. Richard Knazek et al in
1972 (43). These systems were modeled after and intended
to simulate the in vivo capillary system in an attempt to
maintain a more physiologic environment for cultured cells
with regard to nutrient supply, metabolic waste removal,
and pH, while providing a stable pericellular
microenvironment (44).
Schematic diagrams of a hollow fiber bioreactor in
longitudinal and cross-sectional views are presented in
Figures 1 and 2, respectively. The bioreactors consist of
bundles of hollow fibers through which culture media is
continuously perfused in the intracapillary space. The
cells are grown in the extracapillary space which surrounds
the fibers. The walls of the hollow fibers serve as semi-
permeable ultrafiltration membranes. The pore size of the
membrane, depending on the molecular weight cut-off, is
small enough to retain cells and secreted antibody highly
concentrated in the relatively small volume of the
extracapillary space, while permitting gas, nutrients, and
metabolic waste products to freely diffuse across the
membrane due to hydrostatic pressure differences and
concentration gradients. Similarly, macromolecules in the
perfusing media remain within the fiber lumina. Harvest
ports provide access to the extracapillary space for
21
examination of cells and harvest of cell secreted products
(22,45).
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Figure 1.
Schematic Diagram of a Hollow Fiber
Bioreactor
Extracapillary space Intracapillary space
Harvest Nutrients Cells Metabolic
port waste
products
23
Media
Figure 2.
Schematic Diagram of a Hollow Fiber
Bioreactor in Cross Section
Harvest port
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In many reports comparing antibody production using
different cell culture methodologies, hollow fiber
bioreactors have consistently produced the most
concentrated product, ranging from 0.7 to 2.3 mg/ml
(42,46,47). Antibody concentration up to 17 mg/ml has been
reported (48). Antibody production rates for different
cell lines in hollow fiber bioreactors are correlated with
production rates in static culture (47).
In addition to the production of a highly concentrated
antibody product in a small volume, precluding the
necessity for extensive downstream concentrating
techniques, there are many other reported advantages of
hollow fiber bioreactor systems in comparison to other in
vitro systems and in vivo systems. Hollow fiber
bioreactors have been shown to successfully support the
growth of many cell types from different species to include
both anchorage-dependent and anchorage-independent, primary
and established, normal and malignant, fibroblast and
epithelial cells (45). The design and operation of hollow
fibe- bioreactors using continuous perfusion of media
simulates the in vivo environment and provides an
uninterrupted supply of essential nutrients and removal of
metabolic waste products necessary for optimal production
(32). The cells are protected from shear (40,46), which is
important because many hybridomas have been found to be
sensitive to shear, requiring low-shear mixing systems in
agitated cultures (22). Resistance to shear appears to be
25
clone-specific (22).
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Purity of the antibody product has been facilitated by
gradual serum reduction in the culture medium which has
been achieved in hollow fiber systems without significant
inhibitory effect on production (42,45,46,50,51).
Decreased serum utilization also decreases downstream
processing and production costs (42).
The ability to frequently or continuously remove the
product from the bioreactor during the run has a number of
advantages which include decreased potential for
degradation of the product resulting from prolonged
exposure to the culture supernatant containing cellular
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proteases, it minimizes the potential for feedback
inhibition, and minimizes losses in the event of mechanical
failure or microbial contamination (22,26).
Use of microporous hollow fiber bioreactors with large
fiber pore sizes, between 0.2 and 0.5 p, have been
described (26,32,51,52). In comparison to ultrafiltration
membranes, greater antibody production has been achieved
with these microporous membranes (26,52), however the
product is not retained within the small volume of the
extracapillary space and must be concentrated from the
large volume of perfusing media. Studies conducted by
Kidwell demonstrated TGF31 production by 2 hybridoma cell
lines inhibited cell growth and antibody production, and
suggested that retention of inhibitory factors in the cell
space of low MWCO bioreactors was probably accountable for
production differences seen between microporous and
ultrafiltration cartridges (52).
There are cited disadvantages associated with the use
of hllow fiber bioreactors. As with all in vitro systems,
there is the potential for microbial contamination (22,53),
and technical expertise in cell culture is required for
successful operation without contamination (53). The
potential for mechanical failure also exists (22).
Equipment and materials required have been considered
expensive compared to those required for in vivo production
(34).
Because of the nonhomogeneous nature of the hollow
27
fiber bioreactor, cell gradients with variable density,
viability, and productivity exist within the reactor making
it difficult to obtain a representative sample of cells
from the reactor for monitoring (40,48). In studies
conducted by Piret and Cooney, axial sectioning analyses of
hollow fiber bioreactors demonstrated downstream
concentration of viable cells, the monoclonal antibody
product, and high molecular weight proteins. These
findings were attributed to convective fluxes and gravity
sedimentation phenomena. The authors speculated that
downstream polarization of high molecular weight growth
factors was responsible for the downstream concentration of
viable cells. Reversing the direction of media flow
through the reactor in 5 minute cycles improved protein and
cell distribution within the reactor, and the number of
cells recovered from the reactor and the amount of antibody
produced in 6 days was 3 times greater than that produced
by a corresponding reactor without alternation of media
flow direction (48). Concentration gradients of nutrients
and metabolites are also generated within hollow fiber
bioreactors (40).
Hollow fiber bioreactor technology is relatively new
and rapidly evolving and as a consequence there are
frequent modifications in both system components and
recommended operational protocols as more information
becomes available regarding their use.
After reviewing the hollow fiber bioreactor literature,
28
it appeared that these systems had potential as a viable
alternative to the use of mice for small scale monoclonal
antibody production, and as such might serve as a reduction
or replacement technology.
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SECTION 3: OBJECTIVES AND EXPERIMENTAL DESIGN
The First Obiective
One of the objectives of the current study was to
characterize the clinicopathologic changes in mice
associated with the in vivo production of monoclonal
antibodies from ascitic tumors. There are numerous
publications describing the use of mice for monoclonal
antibody production, but the focus has generally been on
production parameters. Although abdominal distention with
ascites formation, the presence of tumor in the abdominal
cavity, and death have been described in many publications,
to the author's knowledge, detailed information describing
the clinicopathologic changes in the animals is absent from
the literature.
Abdominal lesions have been described in nude rats in
which complete Freund's adjuvant was used as the priming
agent in repeated doses ranging from 0.5 to 5.0 ml.
Extensive adhesions were observed in the abdominal cavity
at postmortem examination. With mineral oil or pristane
priming, tumors grew in nodular patches on the mesentery
and infiltrated the peritoneal cavity (16,18). Results of
gross and microscopic examinations of mice with abdominal
plasmacytomas induced by mineral oil or pristane have been
reported (54,55,60).
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A brief protocol review described a veterinarian's
evaluation of 10 ascites mice from the time of pristane
injection through ascites production to provide information
for an Institutional Animal Care and Use Committee.
Animals were observed twice daily for food intake and
behavior. It was reported that for 12 hours after pristane
injection and after the third collection of ascites fluid
by peritoneal tap, the mice exhibited decreased food intake
and decreased exploratory behavior (56).
As there is considerable variation in the biological
behavior of different hybridoma cell lines in mice (4), it
was decided that 5 different hybridoma cell lines would be
evaluated in the current study. Clinical parameters to be
monitored would include body weight measurements, and daily
observation of general appearance, haircoat, posture, level
of activity, and assessment of degree of abdominal
distention. Gross postmortem examinations would be
performed for all animals. The days of abdominal taps and
volume of ascites collected would be recorded, and the
quantity of antibody produced would be determined for each
tap from each mouse. Based on results obtained among the
different hybridoma cell lines to be evaluated, an attempt
would be made to correlate specific experimental
manipulations of animals with observed morbidity and
mortality, with the goal of developing specific criteria
for handling these animals in such a manner as to minimize
morbidity and mortality.
31
Relevant scientific literature was reviewed to assist
in developing an experimental protocol for the mice that
would be applicable to current practices in common use for
production of monoclonal antibodies by the induction of
ascitic tumors in mice.
Parameters Affecting Monoclonal Antibody Production in
Murine Ascites
Mouse Strain, Sex, and Age
As most hybridoma cells have been derived from the
fusion of BALB/c plasmacytomas and BALB/c spleen cells,
hybridoma recipient mice must be histocompatible. In 2
reports, ascites volumes and antibody production were
greater in BALB/c-derived cross-bred F1 hybrids by
comparison to BALB/c parental mice (35,61). In a third
report, no significant difference was observed in ascites
volume or antibody production between the F1 hybrids and
the parental BALB/c mice (4).
In one study, ascites production and antibody
production were shown to be greater in male mice (33),
while another report suggested that there was no
predictable difference between male and female mice with
regard to these production parameters (4). It was
suggested, however that some cell lines may grow slightly
better in one sex of mouse than the other, and for some
cell lines, solid tumors without ascites production tend to
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form in one sex while ascites tumors tend to form in the
opposite sex (4). BALB/c male mice are aggressive and tend
to fight, often requiring single housing, which has been a
deterrent to their use (4).
Retired female breeders have been used because of their
availability, large size, and tendency not to fight (4).
Use of retired female breeders has been recommended in the
UKCCCR guidelines because their abdominal musculature is
assumed to be more distensible, thereby allowing larger
ascites volumes to be tolerated without discomfort (12).
The optimum age range, at the time of hybridoma cell
inoculation, for maximizing antibody production was found
to be 6-11 weeks. Older animals produced as much or more
ascitic fluid but the antibody concentration was
significantly lower (33). A single hybridoma cell line was
used in this study.
Pristane Priming
Pristane is the ascitogenic agent most frequently used
to "prime" the peritoneal cavity for successful growth of
hybridomas as ascitic tumors. In mice which do not receive
pristane prior to hybridoma cell inoculation, solid tumors
may form but little or no ascites is produced (4,25,33,62).
The reported biologic effects of pristane include the
induction of granulomatous inflammation in the peritoneum
primarily consisting of neutrophils and macrophages which
have ingested oil (6,63), immunosuppression (64,65) which
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has been shown to result from a decrease in the
proliferative response of splenic T and B cells to mitogens
and depression of natural killer cell activity (65),
induction of potential growth factors (63,66), and
lymphatic obstruction by oil-ladened neutrophils and
macrophages (6).
Results of previous studies indicate a wide variation
in recommended optimal time schedules and volumes of
pristane to be used for injection prior to hybridoma cell
inoculation.
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In a study conducted by Brodeur et al pristane volumes
ranging from 0.2 to 2.0 ml were investigated, and volumes
of 0.5 ml were found to result in the largest volumes of
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ascites and greatest antibody production (33). In a study
reported by Hoogenraad and Wraight, pristane volumes
ranging from 0 to 0.5 ml were evaluated, and no significant
difference was found between 0.1 and 0.5 ml of pristane
with regard to ascites volume produced, however antibody
concentration data were not presented (62). In an
unpublished study, with large numbers of animals, volumes
of pristane less than 0.5 ml have been shown to result in
suboptimal antibody production (personal communication).
Agents other than pristane have been evaluated for
priming the peritoneal cavity prior to hybridoma
inoculation. One study compared pristane to complete and
incomplete Fruend's adjuvant, proteose-peptone,
thioglycollate, corn oil, and mineral oil as possible
alternatives to the use of pristane (68). Based on the
number of taps/mouse, ascites volume, and antibody
concentration, incomplete Freund's adjuvant was found to be
as good or better than pristane as a priming agent in mice.
In this study, 2 hybridoma cell lines were used. Priming
agents were administered 7 days prior to hybridoma cell
inoculation, and only a single dose of 0.25 ml was
evaluated for each agent.
In another study, using a 0.5 ml dose of incomplete
Freund's adjuvant and 2 hybridoma cell lines, it was found
that the time interval between priming and hybridoma
inoculation could be reduced to 1 day and that as few as 1
x 105 hybridoma cells could be inoculated without
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significant negative impact on ascites production (69).
Results from this study also demonstrated development of
ascites tumors in control mice which received only
incomplete Freund's adjuvant and no hybridoma cells. Jones
et al reported that when 0.1 ml pristane or incomplete
Freund's adjuvant was administered 7 days prior to
hybridoma cell inoculation, ascites volumes were
significantly greater in incomplete Freund's adjuvant-
primed mice with no significant difference in antibody
concentrations in comparison to pristane-primed mice,
therefore resulting in greater antibody production. The
time interval over which animals were tapped was also
shorter for the incomplete Freund's adjuvant-primed mice
(70). A single hybridoma cell line was used in this study.
Hybridoma Cell Inoculum
From results of experiments reported by Chandler, the
optimum number of hybridoma cells for inoculation was found
to be 5 x 10' cells. Cell inoculums of 2 x 106 were
associated with significant mortality, and with doses of 1
x 105 cells, fewer mice developed ascites and the ascites
volume yield was significantly lower. Differences in
number of cells inoculated in these experiments did not
significantly alter antibody concentration (4). Studies
reported by Brodeur et al demonstrated that there was an
inverse relationship between the number of hybridoma cells
inoculated and the duration of time between injection of
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cells and onset of ascites production as well as duration
of survival of the mice (33). Ascites formed sooner with
larger cell inoculums, but shortened survival times could
limit the number of taps possible. Based on ascites
volumes and antibody concentration, they reported optimal
cell dosage to be between 0.6 and 3.2 x 106 cells. Both of
the studies cited here (4,33) were conducted using a single
hybridoma cell line.
Abdominal Paracentesis
It has been recommended that abdominal paracentesis be
performed every 1-3 (71) or 2-3 (72) days with a maximum of
1 (12) to 3 or more (4) taps/mouse. The timing of taps has
generally been determined based on subjective assessment of
degree of abdominal swelling (33,62,67,69,70). Although
generally performed by needle paracentesis with ascites
dripping out due to gravity and pressure (33,68), a vacuum
aspiration technique has also been described and has been
considered advantageous based on more thorough removal of
ascites in a shorter period of time, with potentially less
stress on the animals (4).
Criteria for Establishing the Experimental Design
From information obtained in this literature review,
there appeared to be a lack of consensus regarding
optimization of many procedural parameters for producing
monoclonal antibodies from growth of ascitic tumors in
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mice. It was difficult to make meaningful comparisons
between study results, because for the studies reviewed
here there were differences in the sex, age, and number of
animals used, the hybridoma cell lines used, the volumes
and schedules for priming agents used, the number of
hybridoma cells inoculated, and the production parameters
evaluated.
The experimental regimen selected for use in this
study, as presented in materials and methods in the
following section, was determined in consideration of
results reported in the literature, the requirement that
the regimen be representative of current practices in
common use at MIT and other academic and commercial
institutions, and the obligation that the selected
procedures be in compliance with guidelines established by
the MIT Committee on Animal Care.
The Second Obiective
Another objective of the current study was to compare
monoclonal antibody production in mice versus hollow fiber
bioreactor systems to determine the feasibility of these
systems as potential alternatives to the use of mice. To
the author's knowledge, small scale hollow fiber
bioreactors have not been independently evaluated as a
potential alternative to the in vivo production of
monoclonal antibodies in murine ascites. Data obtained
from 3 of the hybridoma cell lines to be evaluated in mice
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according to the preceding section would be used in this
comparative study. Each of these 3 hybridoma cell lines
would be grown in mice and in each of 3 commercially
available hollow fiber bioreactor systems. The overall
experimental design for this component of the study is
illustrated diagramatically in Figure 3.
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Figure 3.
Experimental Design
Monoclonal Antibody Production in Mice vs. Hollow Fiber Bioreactors
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The following parameters would be used to compare
monoclonal antibody production in mice and bioreactors:
amount and concentration of antibody produced, production
time, equipment and materials required, technical
expertise, humane aspects of the process, time/labor
required, and associated costs.
The hollow fiber bioreactor literature has been
reviewed in the previous section. It should be noted that
of the hollow fiber bioreactor publications cited, only 2
described commercially available systems similar to the
small scale systems that were used in the current study
(45,46). Most of the hollow fiber bioreactor literature
pertains to large scale production.
Criteria for Establishing the Experimental Design
While techniques for operating bioreactor systems were
performed as recommended by each respective manufacturer,
protocols for sample harvesting and system monitoring were
formulated with the intention of maintaining ease of use,
and minimizing financial and time expenditures associated
with the performance of monitoring procedures. The
author's belief was that minimizing procedural complexities
would provide greater incentive for widespread use in the
event that the production data from the bioreactors was
favorable.
Although all of the systems evaluated differed in both
components and operational procedures, whenever possible,
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standardization of materials and operations was
incorporated into the experimental design. Cell culture
media used was the same for all systems, and was the media
in which the cells had been previously adapted for in vitro
growth. The media was supplemented with antibiotics.
Although the use of antibiotics in cell culture medium is
controversial (73,74), it has been recommended that
antibiotics be used in continuous cultures because of the
increased vulnerability of the systems to contamination
over long periods of operation (22). Consideration was
given to the possible use of HEPES in the medium which
would provide sufficient pH control to operate systems in a
warm room, thus precluding the necessity for space
requirements in CO2 incubators. HEPES has been found to
negatively affect some cells types in culture (75),
therefore it was decided that HEPES would not be used in
this study.
Glucose is one of the most important energy and carbon
sources for cultured cells (74), and glucose consumption is
an indicator of cellular metabolic activity in mammalian
cells (75). As previously described, because of the
heterogeneous nature of hollow fiber bioreactors, cellular
activity cannot be measured directly; it is generally
measured indirectly by for example, measurement of glucose
utilization in the media (42,47,48,49). In studies
conducted by Evans, glucose measurements were found to be
more valuable for evaluating bioreactor productivity than
42
measurement of other metabolites. Glucose utilization was
maintained during monoclonal antibody production, while
neither ammonia, lactic acid, or pH were found to correlate
with monoclonal antibody production or inhibition of
monoclonal antibody secretion (47). Based on this
evidence, media glucose was selected to be monitored as a
measure of cellular activity. Media glucose has
traditionally been assayed using standard commercially
available enzymatic test kits. In a recent report by
Kurkela et a, media glucose was measured using a
commercially available blood glucose meter and the results
correlated closely with enzymatically measured glucose
concentrations (42). Because of greater ease of use, it
was decided that glucose measurements would be primarily
monitored with a blood glucose meter. Maintenance of media
glucose at > 150 mg/dl has been described as the optimal
condition for monoclonal antibody production in hollow
fiber bioreactors (49,53) and was selected as the parameter
to be used for determination for fresh media exchanges.
Sandwich ELISAs have been shown to be sensitive,
reproducible, and economical tests for measurement of
murine monoclonal antibodies in hybridoma supernatants and
in ascites (77). It was therefore decided that ELISAs
would be developed for measurement of antigen-specific
antibody in ascites samples and in bioreactor harvests.
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The Third Objective
If results of the data comparing monoclonal antibody
production in mice and hollow fiber bioreactors suggested
that these bioreactors might serve as a viable alternative
to the use of mice, then funding would be sought to
establish a hollow fiber bioreactor core laboratory at MIT
to serve as a model for laboratories at other institutions
with similar needs for a diverse number of monoclonal
antibodies in small scale production lots. Experimental
studies would be conducted in this laboratory to continue
evaluations of hollow fiber bioreactors with larger numbers
of cell lines to improve production through optimization of
environmental conditions
protocols.
for the cells and operational
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MATERIALS AND METHODS
HYBRIDOMA CELL LINES
Five different hybridoma cell lines were selected for
use in this study. These cell lines were selected in part
because of a demonstrated need for particular monoclonal
antibodies for experimental use at this institution, but
also in an attempt to choose hybridomas representative of
varied plasmacytoma fusion partners, varied isotypes of
secreted antibody to include IgM and IgG, and different
subclasses of IgG, and both mouse x mouse and a rat x mouse
heterohybridoma. Cell line designation, antibody
specificity, plasmacytoma fusion partner, and antibody
isotype and subclass are presented in Table 1 for each of
the five cell lines selected.
Hybridomas 2B11, 3C9, 3D6, and 2C6D9 are BALB/c mouse x
mouse hybridomas which were obtained from Laura Trudel in
the hybridoma laboratory of Dr. Gerald Wogan, MIT Division
of Toxicology. Hybridomas 2B11, 3C9, and 3D6 secrete mouse
antibodies directed against aflatoxin B1, 2-amino-3,8-
dimetthylimidazo[4,5-f]quinoxaline, and 4-aminobiphenyl,
respectively (88,89,90). Aflatoxin is a naturally
occurring environmental toxin produced by some strains of
Aspergillus flavus. The heterocyclic amine, 2-amino-3,8-
dimethylimidazo[4,5-f]quinoxaline (MeIQx), is a food
mutagen produced by pyrolysis, and 4-aminobiphenyl (4-ABP)
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SECTION 4:
is an aromatic amine found in fossil fuel combustion
products and cigarette smoke. These compounds are
currently under study by investigators in the MIT Division
of Toxicology. Hybridoma 2C6D9 secretes mouse antibody
directed against bovine serum albumin (BSA).
Hybridoma RMK, which was generously provided by Ann
Marshak-Rothstein from the hybridoma laboratory at Boston
University, is a rat x mouse heterohybridoma which secretes
rat antibody directed against the kappa light chain of
mouse immunoglobulin. This antibody has particular utility
for use in immunoassays to quantitate mouse immunoglobulins
(78,79) as 95-98% of all mouse immunoglobulins contain
kappa light chains (80).
Each of the five hybridoma cell lines was grown in a
group of 20 mice to provide data on monoclonal antibody
production in murine ascites. Additionally, three of these
cells lines, 2B11, 3C9, and RMK, were also grown in each of
three different hollow fiber bioreactor systems to provide
comparative production data from these in vitro systems.
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Legend
Table 1
Selection of Hybridoma Cell Lines
Cell line designation, antibody specificity, plasmacytoma
fusion partner, and antibody isotype and subclass are
presented for each of the five different cell lines used in
this study.
Key to abbreviations:
Me][Qx = 2-amino-3,8-dimethylimidazo[4,5-flquinoxaline
K = kappa. light chain of mouse immunoglobulin
BSA = bovine serum albumin
4-ABP = 4-aminobiphenyl
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Table 1.
Selection of Hybridoma Cell Lines
cell line!
1. 2B11
2. 3C9
3. RMK
4. 2C6D9
5. 3D6
antibody
anti-aflatoxin
anti-MelQx
rat anti-mouse K
anti-BSA
anti-4-ABP
plasmacytoma
Sp2/0-Agl 4
P3-X63Ag8
Sp2/0-Ag 14
Sp2/0-Ag1 4
Sp2/0-Agl 4
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isotype
IgM
IgG2b
IgG 2 a
IgG 1
IgG 1
I_ _ _
__
ASCITES PRODUCTION
Animals
Each mouse x mouse hybridoma, #1, 2, 4, and 5 as
indicated in Table 1, were grown as ascites tumors in 20
CAF,/J male pathogen free mice (Jackson Laboratories, Bar
Harbor, ME). An additional 12 mice served as the CAF1
control group.
The rat x mouse heterohybridoma, #3 as indicated in
Table 1, was grown as ascitic tumors in 20 Fox Chase SCIDTM,
C.B.-17/IcrTac-scidDF male pathogen free mice (Taconic
Farms, Germantown, NY). An additional 12 mice served as
the SCID control group.
Animals were 7 weeks of age at receipt. Animals were
maintained in AAALAC accredited animal facilities at MIT.
Animals were housed 4/cage in polycarbonate shoebox cages
with wire bar lids and Micro-barrierTM filter tops
(Allentown Caging, Allentown, NJ). Lab grade pine shavings
(Northeastern Products Corporation, Warrensburg, NY) were
used for bedding. Cages with bedding for SCID mice were
autoclaved for 20 minutes at 121°C prior to use. CAF1 mice
were fed pelleted rodent chow (Prolab 3000, Agway,
Syracuse, NY) and fresh distilled water in bottles ad
libitum. SCID mice were fed autoclavable pelleted rodent
chow (Prolab 3500, Agway, Syracuse, NY) and autoclaved
distilled water in bottles ad libitum. A 12 hour
light/dark cycle was maintained.
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Animal husbandry was performed according to the
standard operating procedures of the institution and as
described in the Guide for the Care and Use of Laboratory
Animals, NIH Publication No. 86-23, Revised 1985. Animal
husbandry procedures and experimental manipulations with
SCID mice were conducted in a horizontal laminar positive
flow mass air displacement unit (EdgeGARD, Baker Company,
Sanford, ME) using aseptic technique.
All mice were held in quarantine for a minimum of 6
days following arrival to allow for acclimation. Following
release from quarantine, animals were randomized into
groups by weight and identified by ear punch. The protocol
for animal use for monoclonal antibody production in murine
ascites, Protocol #91-003, was approved by the MIT
Committee on Animal Care.
Pristane Priming
On study day -14, each test mouse received a single
intraperitoneal injection of 0.5 ml pristane (2,6,10,14-
tetramethylpentadecane, Sigma Chemical Company, St. Louis,
MO). Animals in the control groups received a single 0.5
ml intraperitoneal injection of 0.9% NaCl, USP (Abbott
Laboratories, North Chicago, IL). Injections of pristane
or saline were administered at the caudal left quadrant of
the ventral abdomen using sterile syringes and sterile 25
gauge 5/8 inch needles.
To determine whether sterility was maintained in
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bottles of pristane under routine use and storage
conditions, samples were obtained, using aseptic technique,
from 4 different bottles of pristane (Sigma Chemical
Company, St. Louis, MO) that were currently in use in the
animal facilities at MIT. Aerobic and anaerobic bacterial
cultures were performed. For aerobic cultures, 1 ml of
pristane was inoculated into 5 ml tryptic soy broth (Remel,
Lenexa, KS) and incubated 18-24 hours at 35°C. Broth
samples were then plated on blood agar/MacConkey agar
biplates (Remel, Lenexa, KS) and incubated 18-24 hours at
35°C. For anaerobic cultures, 1 ml of pristane was plated
on blood agar/MacConkey agar biplates and incubated 46-48
hours at 35°C in an anaerobic jar with a BBLR Gas Pak PlusTM
(Becton Dickinson, Cockeysville, MD). All samples were
protected from light. Results were reported as bacterial
growth or no bacterial growth.
Clinical Observations
All mice were observed at least once daily beginning on
day -14 following administration of pristane. During the
time interval when abdominal taps were performed, animals
were generally observed twice daily. Clinical parameters
evaluated included general appearance, character of the
haircoat, posture, level of activity, and assessment of
degree of abdominal distention. Clinical observations for
test and control animals were recorded.
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Body Weight Measurements
Body weight measurements were made and recorded for
each mouse on study day -14 prior to pristane injection, on
day -7, on day 0 prior to hybridoma cell inoculation, on
days 2, 4, 7, 9, and daily thereafter until study
completion. On days when test animals were tapped to
collect ascitic fluid, before- and after-tap body weight
measurements were recorded.
Hybridoma Cell Inoculation
Hybridoma cells had previously been maintained frozen
in liquid nitrogen in a solution composed of 95% fetal
bovine serum (EndloTM, JRH Biosciences, Lenexa, KS) and 5%
DMSO (Sigma Chemical Company, St. Louis, MO). Cells were
defrosted and grown in static suspension culture prior to
inoculation into mice. Cell culture medium used was
Dulbecco's Modified Eagle's Medium (DMEM) with 4.5 grams
glucose per liter (Gibco, Grand Island, NY). Medium was
supplemented (10 ml/L) with 10 mM MEM non-essential amino
acid solution and 200 mM L-glutamine (Gibco, Grand Island,
NY) for a final concentration of 6 mM L-glutamine. Fetal
bovine serum (EndloM, JRH Biosciences, Lenexa, KS) was
added to 20% v/v final concentration. Cells were expanded
in culture to provide > 20 x 106 cells in log phase growth
for each group of mice. Antibody secretion into the cell
culture supernatant was verified by ELISA for each
hybridoma cell line prior to preparation for inoculation
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into mice. Materials and methods for ELISAs are presented
in a following section under the heading "antibody
cluanti tati on."
On study day 0, cells were counted using a
hemocytometer, and as determined by trypan blue dye
exclusion, a hybridoma cell suspension containing 2 x 106
live cells/ml was prepared. Each test mouse received a
single intraperitoneal injection of 1 x 106 cells in cell
culture medium in a total volume of 0.5 ml. Mice in
control groups received a single intraperitoneal injection
of 0.5 ml cell culture medium without cells. All
injections were administered in the left caudal quadrant of
the ventral abdomen using sterile syringes and sterile 25
gauge 5/8 inch needles.
Abdominal Paracentesis
Abdominal paracentesis was performed when there was
visible moderate to marked abdominal distention. Body
weights of the mice were monitored such that animals were
tapped before exceeding a 20% increase in body weight from
day 0 in accordance with the MIT Committee on Animal Care
Guidelines for the Utilization of Rodents in Experimental
Neoplasia and Ascites Production and the United Kingdom
Coordinating Committee on Cancer Research guidelines (12).
Abdominal taps were performed every 1 to 3 days depending
on the clinical appearance of the mouse and the rate of
ascites production as assessed by the degree of abdominal
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distention. Each mouse was tapped a maximum of three
times.
Abdominal taps were performed using sterile 18 gauge 1
1/2 inch needles inserted into the peritoneal cavity
through the left lateral abdominal wall. Ascites was then
collected by permitting the fluid to drip from the hub of
the needle and directly from the paracentesis site into a
sterile centrifuge tube. The animals were restrained
manually by grasping the loose skin over the shoulder
blades. Gentle digital pressure was applied to the abdomen
and the position of the mouse was altered as needed to
facilitate removal of all the ascites fluid. When no more
fluid could be obtained, animals were weighed, returned to
their cages, and post-tap clinical observations were made.
Abdominal paracentesis was also performed for mice in
the control groups. All control mice were tapped 3 times
during a time interval approximating the abdominal taps for
the test groups. Abdominal paracentesis was performed in
the same manner as for the test animals using sterile 18
gauge 1 1/2 inch needles inserted into the peritoneal
cavity through the left lateral abdominal wall. The mice
were handled and restrained in a manner similar to and for
a time period approximately equal to that necessary to
collect ascitic fluid from test mice. Animals were then
returned to their cages and post-tap clinical observations
were made.
The total volume of ascites fluid collected and the day
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of collection were recorded for each tap for each mouse.
Samples were centrifuged at 550xg for 10 minutes and the
ascites fluid supernatant was then aspirated with a Pasteur
pipette and transferred to a sterile centrifuge tube,
leaving the cell pellet and lipid layer, if present. The
pellet remaining in the original tube was reamed with a
pipette and the sample was centrifuged once or twice more
as needed to completely separate the remaining ascitic
fluid. Centrifugation has been reported as one method
useful for clarification of ascites fluid (81). The
resultant volume of ascitic fluid following centrifugation
was recorded for each tap for each mouse. Samples were
frozen at -20°C until analysis.
Euthanasia
Mice surviving to the third abdominal tap were
euthanized just prior to performing paracentesis. During
the study, any animal with clinical abnormalities which the
author interpreted to be indicative of severe distress or
suggestive that the animal might not survive to the next
observation period was humanely euthanized. Six mice from
each control group were euthanized at the time the last
test animals were euthanized. Euthanasia was performed
using CO2 in accordance with accepted American Veterinary
Medical Association guidelines (82).
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Necropsy
A complete gross necropsy was performed on all animals
in test groups and on six animals from each control group.
Observations noted at necropsy were recorded for each
animal. Organs and tissues were examined in situ then
dissected free and fixed in 10% neutral buffered formalin.
The remaining animals from each control group which were
not euthanized for necropsy at study completion were
released from the study for other experimental use.
Histology
Representative tissues from selected animals were
processed for microscopic examination. Organs and tissues
were trimmed and sectioned. Slides were stained with
hematoxylin and eosin, and were examined microscopically by
Dr. James Murphy. Microscopic lesions observed were
recorded.
Antibody Quantitation
Enzyme linked immunosorbent assays (ELISAs) were used
to screen the cell culture supernatant of hybridoma cells
for secreted antibody prior to inoculation of cells into
mice and bioreactors, and to quantitate in absolute units
the antigen-specific antibody present in each ascites
sample from each mouse, and each harvest from each
bioreactor run. Laura Trudel developed quantitative
indirect antibody ELISAs (83) and performed all of the
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assays for the mouse and bioreactor samples generated in
this study.
Antibody standards were prepared using the Monoclonal
Antibody Purification System (Affi-GelR Protein A MAPSR II
Kit, Bio-Rad Laboratories, Richmond, CA) following the
manufacturer's
anti bo
lines.
by O.D
1.4 0.
di lute
stored
purifi
asciti
reprec
(84).
nm usi
dy from a
Resulti
. at 280
D. units
d in Tris
at 4C.
ed first
c fluid d
ipitation
Antibody
ng the ex
to 1.0 mg/ml.
instructions
scites for e
for purification of monoclonal
ach of the IgG producing cell
ng antibody concentrations were determined
nm using the extinction coefficient for IgG;
equal to 1.0 mg/ml. The antibody was
-2% BSA Buffer with 0.02% sodium azide and
For the IgM cell line, 2B11, antibody was
by 40% ammonium sulfate precipitation of
ialyzed into PBS, followed by
by dialysis against 2% boric acid, pH 6.0
concentration was determined by O.D. at 280
tinction coefficient for IgM; 1.2 0.D. equal
The antibody was diluted and stored as
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Three of the antigens used to determine antigen-
specific antibody concentrations of the ascites and
bioreactor samples were hapten-protein conjugates;
Aflatoxin B1-BSA (88), MeIQx-BSA (89), and 4-ABP-bovine
gamma globulin (90). The rat anti-mouse kappa antibodies
were screened on affinity purified mouse anti-rat IgG
(Boehringer Mannheim, Indianapolis, IN). Antibodies for
2C6D9 were screened on 0.1% BSA (Boehringer Mannheim,
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Indianapolis, IN).
The assays were developed by first performing
checkerboard titrations for each of the 5 antigens in PBS
and were adsorbed overnight at 4C onto 96 well polyvinyl
chloride plates (Dynatech, Alexandria, VA). The plates
were washed with deionized water 3 times and dried. Plates
were then blocked with 0.2% BSA (Boehringer Mannheim,
Indianapolis, IN) in PBS for one hour at room temperature
to control nonspecific binding of antibodies to the
plastic. The plates were then washed 3 times, dried,
covered with parafilm and stored at -20°C.
Standard curves were constructed using concentrations
of purified antibodies starting at 1 pg/ml with two-fold
dilutions to 25 ng/ml in 10% horse serum/PBS (JRH
Biosciences, Lenexa, KS). One hundred microliter samples
were applied to the plate and incubated at 370C for 2
hours. Plates were washed with 0.05% Tween 20 (Sigma
Chemical Company, St. Louis, MO) in PBS 3 times and dried.
Appropriate concentrations of alkaline phosphatase
conjugated goat anti-mouse IgG and IgM and mouse anti-rat
IgG (H&L) (Boehringer Mannheim, Indianapolis, IN) were
determined for each assay by testing varying concentrations
on the standard curve dilutions and selecting the
concentration that provided the highest signal with the
lowest background noise. Specifically, 100 pl of the
enzyme antibody conjugate dilution was added to each well
and incubated for 1 hour at 37°C. The plate was washed and
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dried as above and 100 pl of substrate, 1 mg/ml p-
nitrophenyl phosphate (Sigma Chemical Company, St. Louis,
MO) in 0.1 M Diethanolamine buffer, pH 9.8 (Sigma Chemical
Company, St. Louis, MO) was added to the plate and
incubated for 15 to 45 minutes at room temperature until
the lowest dilution on the standard curve read 1-1.5 0.D.
at 405 nm with a Dynatech MR 7000 automatic ELISA Reader
(Dynatech, Alexandria, VA). The ELISA reader was
programmed to calculate the curve fit for the standards and
to determine the mean and standard deviation of the
duplicates, and concentration of antibody. The assay
sensitivity was high, therefore the samples required
dilution ranging from 1:3000 to 1:250,000 in 10% horse
serum/PBS. The dilution factor was manually recorded and
final concentrations were calculated.
Materials and Time Logs
For the three cell lines which were selected for use in
the segment of the study designed to compare monoclonal
antibody production in mice and hollow fiber bioreactors,
detailed logs were maintained to document materials used
and time spent in labor in all phases of the ascites
production process to include pristane priming, expansion
and preparation of hybridoma cells for inoculation,
inoculation of hybridoma cells into mice, performing
clinical observations, abdominal taps, and euthanasia.
Times recorded were inclusive of set up, experimental
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manipulations, and clean up, but did not include the time
taken to walk to and from the animal facility, as the
animals were housed in a different building than the
offices and laboratory.
Time spent in centrifugation and separation of ascites
was not included in the time/labor figures because every
ascites sample was handled individually as part of the
protocol design. For most applications, murine ascites
would be collected, clarified, and processed in batches, so
the inclusion of these figures in the time/labor
calculations was not deamed appropriate.
Statistical Analyses
Statistical analyses were performed by Dr. Ray Gleason.
Abdominal Tap Days, Ascites Volumes, and Antibody
Quantitation
Differences among mean levels were tested for
statistical significance using a one-way repeated measures
analysis of variance (ANOVA) followed by pairwise
comparisons among group means using the Newman-Keuls test.
Body Weights on Days -14, -7, and 0
Unpaired t-tests were used to compare mean body weights
between pristane-treated and control mice on days -14, -7,
and 0.
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Body Weight Changes from Day 0 to Tap 1
Differences among mean body weight changes and mean
percent changes in body weight between day 0 and the first
abdominal tap for the five test groups were tested for
significance using a one-way ANOVA followed by pairwise
comparisons among group means using the Newman-Keuls test.
Post Abdominal Tap Body Weights vs. Control Body Weights
For comparison of mean post-tap body weights among test
and control groups for each tap, the control mean weights
used were those for the mean study day on which the tap was
performed for the test group. Mean body weights were
tested for significance at each tap using unpaired t-tests.
Mean and Percent Changes in Pre and Post Abdominal Tap Body
Weights
Mean body weights among treated groups were tested for
significance using a one-way ANOVA followed by pairwise
comparisons among group means using the Newman-Keuls test.
Mean Body Weights and Percent Changes Among Taps Within
Groups
Comparisons of mean and mean percent changes in body
weight among taps within groups were made using a one-way
repeated measures ANOVA followed by pairwise comparisons
between taps using the Newman-Keuls test.
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Statistical Significance
The alpha level for statistical significance was set at
0.05. Data are presented as means with the standard
deviation as a measure of dispersion.
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HOLLOW FIBER BIOREACTOR SYSTEMS
Three different hollow fiber bioreactor systems were
selected for use in this study. System selection criteria
included the following: instruments were to be
commercially available, designed to produce monoclonal
antibodies on a laboratory scale ( 100-600 mg antibody/
month/bioreactor), capital costs for equipment were to be
< $7,500, and there was to be a demonstrated willingness on
the part of the manufacturer to provide equipment on loan
for use in the study. Three different bioreactor systems
were identified for which all of the above criteria were
satisfied.
The manufacturers' names have been withheld from this
document for 2 reasons. The objective of this study was to
compare monoclonal antibody production in mice to
monoclonal antibody production in hollow fiber bioreactors,
and in so doing to evaluate hollow fiber bioreactors as a
potential alternative to the use of mice. It was not the
objective of this study to compare different hollow fiber
bioreactor systems. Although attempts were made, to the
extent possible, to reduce experimental variables between
the different bioreactor systems, there are many
significant differences in both system components and
specifications, and in the operational protocols used to
manage these systems, that make direct comparisons between
systems inappropriate. In an effort to avoid comparisons
63
between manufacturers, the bioreactor systems, for purposes
of this document, will be referred to as systems A, B, and
C. Three hybridoma cell lines, 2B11, 3C9, and RMK, were
grown in each of the three different bioreactor systems.
System Components
All 3 systems had the same basic functional components.
The basic design of the bioreactor circuit is illustrated
schematically in Figure 4. All systems were operated in a
media recirculation mode, i.e., the media flow path was in
a continuous unidirectional circuit. Included within the
circuit was a bottle containing cell culture media, a
variable speed pump to maintain media flow, a hollow fiber
bioreactor cartridge, and a means of providing oxygen and
CO2 to the system to support cellular metabolism and
maintain physiologic pH of the media. All systems had an
instrument control module for regulation of media flow rate
and other features unique to each system.
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Figure 4.
Schematic Diagram of a
Hollow Fiber Bioreactor Circuit
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System A
System A had a base unit with a central pump and
stations designed to mount up to 4 hollow fiber cartridge
modules, each with independent media flow path and media
bottle. Three bioreactor cartridges were maintained
simultaneously during this study. The pump motor rotated a
cam on the motor shaft which forced pump pins to depress
thick-walled pump tubing on each module, forcing media by
positive displacement, to flow from the media bottle
through 8 feet of gas permeable silicone tubing, through
the hollow fiber bioreactor cartridge, and back to the
media bottle. There were no media sampling ports in the
system so media samples were obtained directly from the
media bottle. The cap assembly for attachment of tubing to
the media bottle was designed to fit the collar of
commercially available 0.5 and 1 liter media bottles so no
additional bottles were needed.
The base unit weighed 14 lbs. with dimensions of 15.5 x
15.5 x 7.5 inches and was designed to operate within a CO2
incubator. An AC motor cable connected the base unit to an
electronic control unit which was placed outside the
incubator. A power cord connected the electronic control
unit to a standard electrical outlet. A single pump speed
setting could be selected at the control unit. Different
media flow rates could be obtained for each bioreactor
module, ranging from approximately 0 to 50 ml/min, by
altering the length of the pump pins at any individual pump
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station. The control unit also had a pause mode for
temporarily stopping the pump motor. As a safety feature,
the motor would automatically start again after 4 minutes.
The bioreactor cartridge modules with tubing were
supplied sterile. The cap assemblies were not supplied
sterile and were autoclaved at 121°C for 30 minutes prior
to use.
System B
System B had a tray assembly which housed the entire
system. The media pump, operated by a magnetic positive
displacement mechanism, pumped media from a main media
reservoir bottle to a hollow fiber bioreactor cartridge(s).
The system was designed to maintain 1 to 3 bioreactors in
series. The system was operated with a single bioreactor
for this study to preclude any potential downstream effects
of metabolic products from one cell line upon another.
There was a media sampling port with a luer connector
downstream from the bioreactor and a flowmeter followed by
5 meters of gas permeable silicone tubing from which the
media was then directed back to the main media reservoir
bottle. A media transfer bottle was incorporated into the
system with a fill/drain valve to facilitate media
exchanges. The main media reservoir bottle and media
transfer bottle were 1 and 0.5 liter glass bottles,
respectively, to which cap assemblies with 0.2 p vent
filters (Acrodisc CR, Gelman Sciences, Arbor, MI) were
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attached.
The unit weighed 12 lbs. with dimensions of 14 x 11.5 x
11 inches and was designed to operate within a CO2
incubator. A control panel which was attached to the tray
assembly was also housed within the incubator and was
connected via a power cord to a standard electrical outlet.
Media flow rate could be regulated within a range of 0 to
250 ml/min and directional flow of media could be
controlled to move media to and from the transfer bottle
for exchanging media.
The bioreactor cartridges were supplied sterile. The
entire system of tubing and media bottles, exclusive of the
bioreactor, required set up and autoclave preparation, and
was then autoclaved at 1210C for 45 minutes prior to use.
Cleaning and reautoclaving of media bottles with cap
assemblies were required for subsequent media exchanges.
At the completion of each run, the system, exclusive of the
bioreactor, was flushed and reautoclaved.
System C
System C consisted of an instrument module on which was
mounted a removeable rack for placement of 1 to 5
bioreactors each with independent media flow path, and a
pump head which contained individual pump cassettes for
each bioreactor. Media tubing was extended through the
cassette and rotating cylinders within the pump head
depressed the tubing by a peristaltic mechanism, forcing
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media to flow from the media bottle, through an in-line
0.2 p filter, through the hollow fiber bioreactor
cartridge, and back to the media bottle. The purpose of
the filter was to trap any microorganisms potentially
introduced into the system during media changes and thereby
protect the bioreactor from contamination. Media sampling
ports with luer connectors were located downstream from the
bioreactors. Two liter media bottles were supplied with
the system to which cap assemblies with 0.2 p vent filters
(Acrodisc CR, Gelman Sciences, Arbor, MI) were attached.
Hollow fiber bioreactors used in this system were hybrid
reactors. Unlike the conventional hollow fiber bioreactors
containing a cylindrical bundle of fibers within a hard
plastic shell (Figures 1 and 2), the fibers in the hybrid
reactor were arranged in single parallel rows and encased
in a silicone membrane, all within a plastic cartridge
(Figure 5). A gas dome with individual gassing ports for
each bioreactor was located at the back of the bioreactor
cartridge housing, and incubator air was pumped via the
dome and ports to channels outside the gas permeable
silicone membrane, thus providing direct gassing to the
cells in the extracapillary space media of the bioreactor.
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Figure 5.
Schematic Diagram of a Hollow Fiber Hybrid
Reactor
Media out
Media in
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Adapted from Tecnomouse Operator's Manual, Integra Biosciences Inc. Intracapillary space
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The instrument module weighed 11 lbs. with dimensions
of 15 x 12 x 9.5 inches and was designed for operation
within a CO2 incubator. Additional space within the
incubator was required for placement of media bottles. An
AC motor cable connected the instrument module to an
electronic control module which was placed outside the
incubator, and a power cord connected the control module to
a standard electrical outlet. Media flow rate, which was
the same for all bioreactors, could be selected ranging
from 0 to 150 ml/hr. The module could be programmed to
change the media flow rate in fixed or variable increments
as a step function over a specified time interval. The gas
supply setting was dependent on the number of bioreactors
in use. An alarm was displayed in the event of a power
failure. A printer port was available for printer
interface, to print out media flow programs.
The bioreactor cartridges with tubing were supplied
sterile. Two liter media bottles and cap assemblies were
not supplied sterile and were autoclaved at 121°C for 30
minutes prior to use. Cleaning and reautoclaving of media
bottles with cap assemblies were required for subsequent
media exchanges.
Bioreactor Cartridge Specifications
The specifications for the 3 hollow fiber bioreactors
used in this study are presented in Table 2.
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Table 2.
Bioreactor Cartridge Specifications
System A System B System C
Number of fibers
Fiber wall thickness
(microns)
Fiber ID (microns)
Fiber OD (microns)
Fiber length (cm)
Fiber material
Fiber type
Extracapillary space
surface area (m2)
Extracapillary space
volume (ml)
Molecular weight
cut-off (kD)'
Capacity (cells)
1300
8
200
216
9.6
modified
cellulose
isotropic
0.10
7
50
21 09
3150
25
210
260
10.8
cellulose
isotropic
0.14
12
10
>2109
400
20
200
240
15.0
regener-
ated
cellulose
acetate
isotropic
0.04
7
10
>1 09
1 defined at 95°/%; retention
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All fibers were constructed from cellulose-based
materials, and all fibers were isotropic, which defines the
fiber wall as being homogeneous in architecture from the
inner to the outer surface. There were significant
differences in the number and length of fibers in the
cartridges with the hybrid reactor in system C having the
fewest in number and longest fibers. There were
differences in fiber wall thickness, however the internal
luminal diameter of the fibers was very similar for all 3
systems. There were also significant differences in ECS
volume and surface area. The capacity for all cartridges
was specified as > 109 cells.
The molecular weight cut-off (MWCO) for all cartridges
was defined at 95% retention, and cut-offs were selected to
retain the antibody product concentrated within the small
volume of the ECS. The only bioreactor cartridge available
for system C had a 10 kD MWCO, and a cartridge with the
same MWCO was selected for system B. The smallest MWCO
cartridge available for system A was 50 kD.
System Operations
All systems were housed in humidified CO2 incubators
maintained at 370C with 5% CO2 in air. During the study,
incubator temperatures were monitored daily 5-7 days/week
via thermometry and %C02 was monitored using a fyrite CO2
test kit (Bacharach Instrument Company, Pittsburgh, PA).
Techniques for bioreactor system set up, operation, and
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maintenance were performed as recommended by each
respective manufacturer according to instructions contained
in the operator's manuals and recommendations made by
technical service representatives. Each bioreactor run was
65 days. Pilot runs were conducted with each system to
gain competence in technical procedures and to evaluate
media conditions and operational protocols.
All manipulations of cells and bioreactor systems were
performed in a Class II biological safety cabinet
(SterilGARD, Baker Company, Sanford, ME) with the exception
of system C for which system set up and cell inoculations
were performed in a safety cabinet but subsequent
manipulations of the bioreactor system were performed
within the incubator in which the system was housed. The
individual bioreactor cartridge modules for system A and
the bioreactor tray assembly for system B were easily
disconnected and moved to and from the incubator and safety
cabinet. Because of tubing and gassing port connections to
the instrument module and the larger 2 liter media bottles
used in system C, movement of bioreactors was more
difficult, and the manufacturer recommended that
manipulations be performed within the incubator.
All systems were handled using strict aseptic
technique. Latex gloves were worn and ports of entry which
were accessed, such as the luer connections on ECS harvest
ports and ICS media sampling ports, and media bottle cap
connections, were thoroughly cleaned using individually
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packaged alcohol pads (Baxter Inc., McGaw Park, IL) before
disconnection and manipulation. All materials used were
sterile. An aliquot was taken from each media bottle after
addition of supplements and incubated at 37°C for 24 to 48
hours to check for sterility prior to use. As an
additional precaution for system C, because manipulations
were not performed within a safety cabinet, luer caps with
injection septa provided with the system were placed at all
ECS and ICS sample ports and were cleaned with 10%
povidone-iodine (Betadine, Purdue Frederick Company,
Norwalk, CT) prior to each use. To maintain the integrity
of the septa, non-coring needles (Huber needles, Access
Technologies, Skokie, IL) were used.
Media Composition
The same cell culture medium was used for all three
systems and cell lines and was the medium to which the
cells had been previously adapted in culture. Medium used
was Dulbecco's Modified Eagle's Medium (DMEM) with 4.5
grams glucose per liter supplemented (10 ml/L) with 10 mM
MEM Eagle non-essential amino acid solution, 200 mM L-
glutamine, and 10,000 unit/ml penicillin/10,000 pg/ml
streptomycin mixture (BioWhittaker, Inc., Walkersville, MD)
for a final concentration of 6 mM L-glutamine, 100 units/ml
penicillin, and 100 pg/ml streptomycin. Intracapillary
space (ICS) perfusing media was supplemented initially with
1% fetal bovine serum (EndloTM, JRH Biosciences, Lenexa, KS)
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and was subsequently reduced to 0% after bioreactor media
consumption exceeded 1 liter/week. Use of ICS media with
1% serum was resumed if significant decreases in cell
viability and/or glucose consumption were observed
following removal of serum from the ICS; subsequent
reduction in ICS serum concentration was from 1% to 0.5%
before complete removal of serum from the media.
Extracapillary space (ECS) media was initially supplemented
with 10% fetal bovine serum and was subsequently reduced to
5% after demonstration of stability in cell viability and
glucose consumption following removal of serum from the ICS
media. Use of ECS media with 10% serum was resumed if
significant decreases in cell viability and/or glucose
consumption were observed following reduction of serum to
5%. Serum reductions in the ICS and/or ECS media were not
performed if cell viability and glucose consumption
remained low. The same lot of fetal bovine serum (lot#
2B2032) was used for all bioreactor media.
Cell Inoculation
Hybridoma cells from lines 2B11, 3C9, and RMK had been
previously frozen in a freezing solution composed of 95%
fetal bovine serum (EndloTM, JRH Biosciences, Lenexa, KS)
and 5% DMSO (Sigma Chemical Company, St. Louis, MO) and had
been maintained frozen in liquid nitrogen. Cells were
defrosted and grown in static suspension culture prior to
inoculation into bioreactors. Cells were placed in
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supplemented DMEM as described above with 20% fetal bovine
serum after defrosting. Approximately one week after
defrosting, the serum was reduced to 10%. Cells were
adapted to growth in media with 10% serum for 3-8 weeks.
Cells were expanded in culture to provide the necessary
number of cells in log phase growth for each bioreactor.
Antibody secretion into the cell culture supernatant was
verified by ELISA as previously described for each
hybridoma cell line prior to preparation for inoculation
into bioreactors. Bioreactor systems were set up and
flushed with media on day -1, and visually inspected for
sterility prior to inoculation of cells on day 0.
Concentration of bioreactor cell inoculums was
standardized such that the number of cells inoculated per
unit volume of extracapillary space was identical for all
systems. On study day 0, cells were counted using a
hemocytometer, and a cell suspension containing 8.6 x 106
live cells/ml as determined by trypan blue dye exclusion
was prepared in 100% conditioned media for inoculation.
Limiting Dilution
All cell lines were tested for stability by limiting
dilution (85) at the beginning of each run using cells
retained from bioreactor inoculations, and at the end of
each run using cells obtained from the last bioreactor ECS
harvests. In brief, cells were diluted in BALB/c
thymocyte-containing media and plated into 96 well plates.
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The supernatant from wells which developed clones were
tested by ELISA as previously described, and stability of
each cell line was measured as the % of clones which tested
positive for antibody secretion.
Media Monitoring
Media was recirculated in all 3 systems. Media flow
rates were 50 ml/min, 100 ml/min and 100 ml/hr, for systems
A, B, and C, respectively. The concentration of glucose in
the perfusing ICS media was determined 3 times weekly at
the time of product harvests using a commercially available
glucometer (One TouchTM, Lifescan, Inc., Milpitas, CA). Ten
microliters of media at 37°C was placed on a test strip and
measurements were recorded in mg/dl from the LED display on
the instrument. Samples were tested in duplicate and the
mean glucose value for each sample was used to calculate
glucose consumption rate. Cleaning and maintenance of the
glucometer, and calibration checks as determined by
measurement of control samples, were performed according to
the manufacturer's instructions.
Fresh ICS media was supplied as necessary to maintain
media glucose concentrations at 150 mg/dl. At the
minimum, media was exchanged once weekly because of
concerns for spontaneous decomposition of glutamine at 37°C
(86,87).
Glucose standard solutions and selected ICS media
samples from pilot and study runs were retained (N=33), and
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mean glucose measurements from the duplicate tests obtained
using the glucometer were compared with glucose
measurements obtained using a standard diagnostic test kit
(Procedure #115, Sigma Diagnostics, St Louis, MO).
Agreement between the two methods was assessed
statistically using the method of Bland and Altman (91),
Pearson's product moment correlation, and coefficient of
variation.
Antibody Product Harvests
Antibody product was harvested from the bioreactor
extracapillary space per manufacturer's instructions three
days a week (Monday, Wednesday, and Friday) starting with
the initial harvest on day 4 (systems A and B) or day 7
(System C). For system A, spent media with cells was
aspirated from the ECS and then the ECS was subsequently
refilled with fresh media. For systems B and C, fresh
media was simultaneously flushed into the ECS at one
harvest port as spent media with cells was aspirated from
another harvest port. For system A, the volume of product
harvests was dependent on the volume of media and cells in
the ECS. For system B, 5.0 ml aspirates were obtained on
harvest days 4 through 11, and 10.0 ml aspirates were
obtained from days 14 through 65. For system C, 5.0 ml
aspirates were obtained for all harvests.
Live and dead cell counts, as determined by trypan blue
staining using a hemocytometer, were recorded for each
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harvest. Cell viability (%) was calculated. Samples were
centrifuged at 550xg for 10 minutes, the supernatant was
aspirated from the cell pellet, and aliquots were stored at
4°C and -200C. Sample volumes before and after
centrifugation were recorded for each harvest.
Antibody Quantitation
Antibody from each harvest sample from each bioreactor
was quantitated using the identical indirect antibody
ELISAs that were used to measure antibody in mouse ascites
samples. Materials and methods for ELISAs have been
previously described. Samples were batched and analysed at
the conclusion of the bioreactor runs.
Materials and Time Logs
Detailed logs were maintained to document materials
used and time spent in labor for all aspects of bioreactor
operation to include system set up and media flush
procedures, cell expansion, preparation, and inoculation,
sample collections from the ICS and ECS, media glucose
testing, cell counts, media preparation, media exchanges,
and cleaning and autoclaving of glassware. Times recorded
were inclusive of set up, experimental manipulations, and
clean up.
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SECTION 5: RESULTS
PART 1: MONOCLONAL ANTIBODY PRODUCTION IN MURINE ASCITES
CLINICAL OBSERVATIONS
The incidence of clinical abnormalities observed in
ascites mice during the study are presented in Table 3.
All animals in the control groups remained clinically
normal throughout the study. No abnormal clinical
observations were made for any test animals during the two
week period following injection of pristane. Clinical
abnormalities observed in mice during the ascites
production process were similar among groups, yet differed
in the rapidity of progression and severity, and the
incidence of specific abnormalities (see Table 3). These
results are discussed more completely under the individual
group results which follow.
The onset of clinical abnormalities in all groups was
generally related to the development of ascites as
determined by visible abdominal distention and increasing
body weight. The range of days over which the first
abdominal tap was performed was indicative of the time of
initial ascites development for each group. This data is
presented in Figure 6. Initial clinical abnormalities
noted in all groups included roughened haircoats, hunched
posture, and progressively increasing abdominal distention.
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For animals in all groups, the severity of clinical
abnormalities increased progressively over time, and as the
number of abdominal taps increased. Decreases in activity,
palpable abdominal masses, thin appearance, and evidence of
dehydration as determined by decreased'skin turgor and
enophthalmos were most often noted later in the time course
of study.
There were a number of clinical abnormalities seen
during the observation period following abdominal
paracentesis. These abnormalities were observed in some
animals from all groups and included roughened haircoats,
hunched posture, decreased activity often associated with
the observation of mice huddling together in the cage,
tachypnea and in some cases dyspnea, and pallor which
presented as a blanching of normal pink color which was
most evident on the muzzle and ears. These signs were most
often transient, but in 19 animals, from 4 of the 5 test
groups, these signs were severe and persistent leading to
death or euthanasia following the first or second abdominal
tap. Twelve of these 19 animals were from Group 2C6D9.
All animals that died following paracentesis did so within
approximately 30 minutes from the time of tap.
Persistent leakage of ascites fluid from the abdominal
tap site was observed in one group of animals. This
observation is discussed in more detail in the individual
group results for Group RMK.
Small subcutaneous soft tissue nodules were grossly
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visible and palpable in some animals from all groups, at
the caudal left ventral abdomen, the site of
intraperitoneal injection of pristane on day -14, and
hybridoma cells on day 0. Nodules observed post-pristane
were apparent in 8 animals from 4 groups, and were first
noted on study day 0 prior to hybridoma cell injection.
The nodules were raised and ranged in siz
in diameter. In 5 of the 8 animals which
subcutaneous nodules post-pristane, the n
in size or became inapparent within 7-14
initial observation.
Nodules observed post-hybridoma cell
first noted 13 to 20 days following hybri
inoculation in 14 animals from 3 groups.
raised and ranged in size from 2 to 5 mm
nodules increased in size over time in 9
e from 2 to 6 mm
developed
iodules decreased
days from the
injection
doma cell
The nodu
in diamet
animals.
were
les
er.
No
were
The
change in nodule size over time was noted for the remaining
5 animals.
Individual group results follow Table 3.
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Legend
Table 3
Incidence of Clinical Abnormalities in Ascites Mice
For each clinical observation listed, incidence is
presented as the total number of animals in each group
which were observed to have the indicated clinical sign.
Detai led
provided
descriptions of'each clinical observation are
in the text.
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Table 3.
Incidence of Clinical Abnormalities in
Ascites Mice
CAF1 Mice
Control 2B1 1 3C9 2C6D9 3D6
Number of animals 12 20 20 20 20
Daily observations
Clinically normal
Subcutaneous mass at
injection site post-pristane
Subcutaneous mass at
injeciton site post-hybridoma
Rough hair coat
Hunched posture
Decreased activity
Palpable abdominal mass
Thin appearance
Dehydration
Animals euthanized
prior to taps
Animals died prior to taps
Abdominal distension
Animals tapped
Animals euthanized
post-tap 1
Animals died post-tap 1
Animals euthanized
post-tap 2
Animals died post-tap 2
Animals euthanized at tap 3
12 0 0 0 2
0 4 1 2 0
0 0 10 0 3
0 20 20 20 18
0 20 20 20 18
0 3 8 18 12
0 1 6 0 6
0 4 3 1 2
0 3 0 18 1
0 1 0 0 0
0 0 0 1 0
0 19 20 19 18
0 19 20 19 18
0 0 0 1 0
0 0 0 1 0
0 4 1 7 1
0 0 1 3 0
0 15 18 7 17
Observations during post-tap period
Rough hair coat 0 19
Hunched posture 0 19
Decreased activity 0 19
Increased respiratory rate 0 19
Pallor 0 19
Ascites leak from tap site 0 0
10 19 5
17 19 6
17 19 8
4 19 3
7 19 10
0 0 0
SCID Mice
Control RMK
11 20
11 0
0 1
0 1
0 20
0 20
0 5
0 0
0 1
0 0
0 0
0 0
0 20
0 20
0 0
0 0
0 0
0 0
0 20
O0
0 10
0 9
0 11
0 3
0 9
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CLINICAL OBSERVATIONS (cont'd)
Group 2B11
One mouse in this group was euthanized following
pristane and hybridoma cell injections, but before
abdominal paracentesis. Seven days following hybridoma
cell inoculation, this mouse had a palpable caudal
abdominal mass. On day 9 the mouse appeared thin, had lost
weight, was dehydrated, had a roughened haircoat and
hunched posture, and was euthanized. Postmortem lesions
for this mouse are described under Necropsy Observations.
All animals in this group exhibited clinical
abnormalities following abdominal tap including hunched
posture, roughened haircoat, decreased activity, increased
respiratory rate, and pallor of the muzzle and ears. These
signs were generally transient and of relatively mild
severity with the exception of 4 animals with persistent
and severe abnormalities necessitating euthanasia following
the second abdominal tap.
Group 3C9
This group had the greatest incidence of subcutaneous
soft tissue masses at the site of intraperitoneal
injection. Masses developed in 10 of 20 animals between
days 13 and 20 following hybridoma cell inoculation. Six
animals in this group developed palpable abdominal masses
during the study.
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Clinical abnormalities following abdominal tap were
generally transient and mild to moderate in severity with
two exceptions. One animal died within 30 minutes
following tap 2, and one animal was euthanized immediately
following tap 2 because of marked pallor, dyspnea, and
recumbency.
Group 2C6D9
Clinical abnormalities were the most rapidly
progressive and severe in this group as is demonstrated by
the greatest incidence of mortality and euthanasia prior to
tap 3. Ten days post inoculation of hybridoma cells, and
prior to any abdominal taps, one mouse in this group
evidenced weight loss, appeared thin, had a roughened
haircoat, hunched posture, and a palpable caudal abdominal
mass. This animal was found dead in the cage the following
day. Postmortem lesions for this animal are described
under Necropsy Observations.
Of the 19 animals in this group which were tapped to
collect ascites, all demonstrated transient or persistent
clinical abnormalities post tap which included roughened
haircoat, hunched posture, decreased activity, pallor of
the muzzle and ears, increased respiratory rates and in
some cases dyspnea. One animal died within 30 minutes of
tap 1, and one animal was euthanized following tap 1.
Three animals died within 30 minutes of tap 2, and an
additional 7 animals were euthanized following tap 2
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because of persistent and severe clinical abnormalities.
The incidence of animals exhibiting decreased activity and
signs of dehydration was also greatest in this group.
Group 3D6
Two animals in this group remained clinically normal
throughout the study, produced no ascites, and so were not
tapped. Postmortem lesions were, however, observed in both
of these animals and are described under Necropsy
Observations. Clinical abnormalities following abdominal
tap in this group were generally transient and of mild to
moderate severity. One animal was euthanized following tap
:2 because of more severe and persistent clinical
abnormal i ti es.
Group RMK
There was 100% survival to tap 3 in this group.
Overall, by comparison to other groups, clinical
abnormalities were generally least severe in this group.
Clinical abnormalities observed following abdominal taps
were also generally transient and mild. It was the
impression of the author that a number of these animals
could have been tapped at least one additional time without
unduly compromising their clinical condition.
Nine animals in this group had persistent leakage of
ascites from the abdominal tap site. This observation was
noted only in this group. The fur on the left lateral
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abdomen around and ventral to the tap site was observed to
be wet with clear fluid during observations made the day
following abdominal tap. The leakage of ascites had
usually resolved by 2 days following abdominal tap.
Abnormal clinical signs were observed in one control
animal for this group during the quarantine period. This
animal appeared thin, had hunched posture, roughened
haircoat, dyspnea, decreased activity, and was euthanized.
The prominent findings on post mortem examination included
hemothorax and hemoperitoneum suggestive of trauma or a
congenital cardiovascular anomaly. Bacterial cultures and
mycoplasma cultures submitted at the time of necropsy were
negative. As a result of this animal being euthanized, the
control group for Group RMK was reduced to 11 animals.
TIME INTERVALS FOR ABDOMINAL TAPS
The time interval, represented by the range of days
during which abdominal taps 1, 2, and 3 were performed for
each group, and the mean + 1 standard deviation for each
tap interval are presented in Figure 6. Significant
differences were observed between groups in the range of
days during which abdominal taps were performed. For Group
2B11 and 2C6D9, the development of ascites was relatively
synchronous among animals within each group, and
consequently, the days on which abdominal taps 1, 2, and 3
were performed were nearly the same for all animals in each
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group. The range of days during which each tap was
performed was progressively greater for Groups 3C9, 3D6,
and RMK, respectively, indicating greater variability among
animals in the time of ascites development, and
consequently, the time of abdominal taps.
In comparisons of mean tap days between groups, the
same trend was observed for taps 1, 2, and 3. For tap 1,
the mean day of tap for Group 3D6 (day 22) was
significantly greater than that for Groups RMK (day 16) and
3C9 (day 15), which were significantly greater than that
for Group 2B11 (day 13) which was significantly greater
than that for Group 2C6D9 (day 11).
For tap 2, the mean day of tap for Group 3D6 (day 24)
was significantly greater than that for Groups RMK (day 18)
and 3C9 (day 17), which were significantly greater than
·that for Group 2B11 (day 15) which was significantly
greater than that for Group 2C6D9 (day 13).
For tap 3, the mean day of tap for Group 3D6 (day 26)
was significantly greater than that for Groups RMK (day 20)
and 3C9 (day 19), which were significantly greater than
that for Group 2B11 (day 17) which was significantly
greater than that for Group 2C6D9 (day 15).
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Figure 6.
Time Intervals for Abdominal Taps
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BODY WEIGHT MEASUREMENTS
A significant difference in mean body weights was
observed for the CAF1 mice versus the SCID mice at day 0;
the mean body weight for the SCID mice was significantly
lower than the mean body weight for the CAF1 mice. As a
result of this difference, no body weight comparisons were
subsequently made between CAF1 mice (Groups 2B11, 3C9,
2C6D9, and 3D6) and SCID mice (Group RMK).
Study Days -14 Through 0
No significant differences were observed in mean body
weights for the CAF1 control versus pristane treated test
animals or the SCID control versus pristane treated test
animals at days -14, -7, and 0.
No significant difference in body weights among CAF1
control and test animals, and SCID control and test animals
were noted at day 0.
Study Day 0 to the First Tap
Mean body weights in grams 1 standard deviation and
mean percent increase in body weights between day 0 and the
before tap weight at the first abdominal tap + 1 standard
deviation are presented for each group as follows:
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Group Day 0 Tap 1 % Increase
2B11 30.26 + 1.73 34.79 + 2.27 15.00 3.46
3C9 29.71 + 2.00 35.26 + 2.01 19.24 + 4.27
2C6D9 30.75 + 2.35 33.86 + 3.36 10.11 + 7.66
3D6 29.65 + 1.93 34.85 + 2.78 17.59 + 6.36
RMK 25.07 + 2.25 30.41 + 3.04 23.77 + 6.27
The mean percent increase in body weight was
significantly greater for Group RMK, and significantly less
for Group 2C6D9, in comparison to other groups. The mean
percent increase in body weight between day 0 and the
before tap weight at the first abdominal tap for all groups
combined was 17.14%.
Study Day 0 Through the End of Study
Because of considerable variability in the time of
development of ascites and the range of days during which
animals were tapped, both within and between groups, as
presented in Figure 6, and because of the impact of this
variability on body weight measurements, body weight
comparisons within and between groups over time were not
generally considered to be meaningful.
For comparisons of mean body weights between individual
test and control groups for each specific tap (1, 2, or 3),
test group body weights were compared to the control group
body weight on the mean study day which the specific tap
was performed for the test group. Control group weights
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were compared to the post-tap weights (after removal of
ascites), for the test groups as these weights were
considered to more accurately reflect the actual body
weight of the animals.
Mean post-tap body weights for the test groups + 1
standard deviation at taps 1, 2, and 3 were as follows:
Group Tap 1 Tap 2 Tap 3
2811 30.79 + 2.15 28.27 + 2.56 28.89 2.79
3C9 32.84 + 2.11 30.98 + 2.75 29.87 + 3.02
2C6D9 30.36 + 2.91 27.79 + 2.38 27.61 1.62
3D6 32.38 + 2.39 31.21 + 2.08 30.57 + 2.14
RMK 27,,80 + 2.46 29.66 + 3.21 30.36 + 3.45
Group 2B11
Because the development of ascites, and consequently,
days of abdominal taps were relatively synchronous in this
group, mean body weights for this test group and the
corresponding control group have been graphed over time, to
include the mean percent drop in body weight for the test
group at taps 1, 2, and 3 (Figure 7). Body weights for the
test group began to increase on day 10 relative to the
control weights, continued to increase, and then reached a
plateau between day 11 and the first abdominal tap on day
1;3. The mean percent drop in body weight was significantly
greater at the first tap (11.50%) in comparison to taps 2
and 3 (6.04 and 5.24%, respectively). There was no
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significant difference between the post-tap weight for the
test group and the control group weight following tap 1.
The post-tap weights for the test group were significantly
lower than the control weights following taps 2 and 3.
Likewise, post-tap weights within Group 2B11 were
significantly lower following taps 2 and 3 when compared to
tap 1.
Group 3C9
The mean percent drops in body weight were not
significantly different for tap 1 (7.18%), tap 2 (7.11%),
and tap 3 (5.75%) in this group. There were no significant
differences between the post-tap weights for the test group
following taps 1, 2, and 3 and the corresponding control
weights, however, post-tap body weights did significantly
and progressively decrease within Group 3C9 from taps 1
through 3.
Group 2C6D9
Development of ascites, and consequently, days of
abdominal taps were relatively synchronous in this group.
Mean body weights for this test group and the corresponding
control group have been graphed over time, to include the
mean percent drop in body weight for the test group at taps
1, 2, and 3 (Figure 7). Body weights for the test group
began to increase on day 9 relative to the control weights,
continued to increase between days 9 and 10, and then
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reached a plateau between day 10 and the first abdominal
tap on day 11. The mean percent drop in body weight
decreased significantly from the first through the third
abdominal tap (10.23, 5.61, and 3.47%, respectively).
There was no significant difference between the post-tap
weight for the test group and the control group weight on
day 11 following tap 1. The post-tap weights for the test
group were significantly lower than the control weights
following taps 2 and 3. Likewise, post-tap weights within
Group 2C6D9 were significantly lower following taps 2 and 3
by comparison to weights following tap 1.
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Figure 7.
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Group 3D6
The mean percent drops in body weight were not
significantly different for tap 1 (7.00%), tap 2 (5.40%),
and tap 3 (5.21%) in this group. There were no significant
differences among the post-tap weights for the test group
following taps 1, 2, and 3 and the corresponding control
weights, however, post-tap body weights did significantly
decrease within the test group from tap 1 to 2.
Group RMK
The mean percent drops in body weight were
significantly greater for tap 1 (8.45%) and tap 3 (6.99%)
in comparison to tap 2 (4.31%) in this group. There were
no significant differences between the post-tap weights for
the test group and the corresponding control weights
following tap 1, however, post-tap body weights for the
test group were significantly greater than the
corresponding control weights following taps 2 and 3.
Likewise, post-tap weights within Group RMK were
significantly greater at taps 2 and 3 in comparison to
weights at tap 1.
Correlation Between Body Weights and Clinical Observations
In examination of individual animal data, no definitive
correlation could be made between the magnitude of the
percent drop in body weight at the time of abdominal taps
and the presence or absence of post-tap clinical
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abnormalities such as pallor, tachypnea, hunched posture
and decreased activity.
ASCITES MICE SURVIVAL
The survival of ascites mice over time is presented in
Table 4. Survival is represented by the number of animals
tapped in each group at taps 1, 2, and 3, respectively.
For Group RMK, no animals died or were euthanized during
the study, therefore survival was 100% at all timepoints.
Two animals in Group 3D6 did not produce ascites and so
were not tapped. Survival percentages for Group 3D6
corrected for these two animals not tapped would be 100,
100, and 95%, respectively, for taps 1, 2, and 3.
Number of animals tapped for all groups for taps 1, 2,
and 3, respectively, ranged from 90-100%, 85-100%, and 35-
100%, respectively. For all groups combined, overall
survival to tap 1 was 98%; to tap 2 was 96%; and to tap 3
was 79%.
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Table 4.
Ascites Mice Survival
Number of Animals Tapped
cell
line
animals
tap 1
2B11
3C9
RMK
2C6D9
3D6 1
19/20
20/20
20/20
19/20
18/20
animals
tap 2
(95%)
(100%)
(100%)
(95%)
(90%)
19/20
20/20
20/20
17/20
18/20
(95%)
(100%)
(100%)
(85%)
(90%)
animals
tap 3
15/20
18/20
20/20
7/20
17/20
Two mice inoculated with 3D6 cells did not produce ascites.
1 00
(75%)
(90%)
(100%)
(35%)
(85%)
BACTERIAL CULTURE OF PRISTANE
No bacterial growth was identified in any samples
obtained from the 4 bottles of pristane which were
submitted for aerobic and anaerobic bacterial cultures.
NECROPSY OBSERVATIONS
Incidence of gross lesions observed in mice at necropsy
are presented in Table 5.
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Legend
Table 5
Incidence of Gross Lesions at Necropsy in Ascites Mice
For each gross lesion listed, incidence is presented as the
total number of animals in each group which were observed
to have the indicated lesion.
Detailed descriptions of each gross lesion are provided in
the text.
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Table 5.
Incidence of Gross Lesions at Necropsy in
Ascites Mice
CAF1 Mice SCID Mice
Control 2B1 1 3C9 2C6D9 3D6 Control RMK
Number of animals 6 20 20 20 20 6 20
Mean day of necropsy 31 16 19 13 26 32 20
Abdominal cavity
Ascites 0 0 0 0 0 0 3
Hemoperitoneum 0 9 16 14 12 0 1
Disseminated tumor 0 19 20 18 17 0 19
Solid tumor mass 0 13 13 10 19 0 3
Peritesticular mass 0 3 11 0 5 0 1
Adhesions 0 12 2 9 12 0 1
Diaphragm - nodules 0 0 1 4 1 0 17
Diaphragm - plaques 0 0 10 0 12 0 0
Hepatomegaly 0 4 1 2 7 0 2
Splenomegaly 0 2 5 0 7 0 6
Renomegaly 0 1 0 0 3 0 1
Ureter dilated 0 1 1 0 0 0 1
Bladder distended 0 0 0 2 1 0 1
Bowel dilated 0 0 0 0 5 0 0
Ventral edema 0 0 0 0 0 0 7
Thoracic cavity
Enlarged lymph nodes 0 12 9 0 11 0 9
Mediastinal mass 0 0 0 0 1 0 3
Injection site
Subcutaneous mass 0 2 10 1 2 0 4
Abdominal wall mass 0 1 10 0 1 0 2
Peritoneal mass 0 3 1 0 0 0 2
Abdominal tap site
Subcutaneous hemorrhage 0 18 20 16 17 0 18
Muscle hemorrhage 0 3 0 3 2 0 0
Subcutaneous mass 0 0 0 0 0 0 12
Edema 0 0 0 0 0 0 4
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Lesions in the Abdominal Cavity
Hemoperitoneum was frequently observed in all groups of
CAF1 mice, with incidences ranging from 9-16/20 mice.
Hemoperitoneum was only observed in 1/20 SCID mice from
Group RMK, and an additional 3 mice from this group had
clear ascitic fluid in the abdominal cavity at the time of
necropsy.
With the exception of one animal from Group 2B11 and
one animal from Group 2C6D9, all test animals examined from
all groups had disseminated tumor and/or solid tumor masses
in the abdominal cavity. The disseminated tumor was
characterized by intraabdominal seeding with multi-
lobulated, nodular to irregular, reddish to tan-white soft
tissue, primarily involving the mesentery from stomach to
rectum, and also involving dorsal lumbar, perirenal,
peritesticular, and caudal abdominal/cranial pelvic areas
with an apparent tropism for abdominal fat. Solid tumors
were characterized as distinct and generally larger soft
tissue masses, which differed from, but often occurred
with, the diffusely seeded tumor. Solid tumor masses
ranged in size from approximately 0.5 cm3 to 3.5 x 2.2 x
1.5 cm. The most common location of solid tumors was the
left caudal, ventrolateral abdomen, which was the site of
hybridoma cell injection. Solid tumors were also observed
in other abdominal and pelvic locations. Disseminated and
solid tumors were seldom attached to the peritoneum.
Presence of solid tumor masses in the peritesticular
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fat was also frequently observed.with incidences ranging
from 1 to 11/20 mice in 4 of the 5 test groups. The
highest incidence of peritesticular tumor masses was 11/20
in Group 3C9. No peritesticular tumor masses were observed
in Group 2C6D9.
Abdominal adhesions were observed in animals from all
test groups with incidences ranging from 1-12/20 mice.
Adhesions were observed in only 1 SCID mouse from Group
RMK, and in 2 mice from Group 3C9, with incidences of 9,
12, and 12/20, respectively for Groups 2C6D9, 2B11, and
3D6. Abdominal adhesions were characterized by fibrous
tissue attachments between abdominal structures which
included the tumor, abdominal wall, diaphragm, liver,
gastrointestinal tract, kidneys, ureters, bladder, seminal
vesicles, and testicles.
Singular or multiple tumor nodules were observed
attached to the hepatic surface of the diaphragm in animals
from 4 of the 5 test groups. The incidence of
diaphragmatic nodules was much greater in SCID mice from
Group RMK (17/20), than the incidences observed in 3 of the
4 groups of CAF, mice, Groups 3C9, 3D6, and 2C6D9, which
ranged from 1-4/20 mice, respectively. Nodules were
frequently attached to the hepatic-diaphragmatic ligament,
were usually tan in color and well-circumscribed, ranging
in size from approximately 0.1 to 0.5 cm3.
Plaques or linear lesions that appeared to be within
the diaphragm were observed in 10/20 mice from Group 3C9,
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and 12/20 mice from Group 3D6. Similar lesions were not
observed in any other groups. Plaques were characterized
as raised, white to tan foci, usually multiple, that
appeared to be within the diaphragm, and were 0.3 cm2 in
diameter. Linear lesions were also white to tan and
raised, and appeared to be within the diaphragm.
Microscopic examination of selected tissues performed to
define this gross lesion confirmed infiltration of tumor
cells into the diaphragm.
Hepatomegaly, splenomegaly, and renomegaly were
observed with variable incidence in the test groups.
Ureteral dilation and bladder distention were infrequently
observed among test groups. Five of 20 animals in Group
3D6 had intestinal dilation. Organ dilation or distention
was generally related to distal constrictive lesions
created by tumor growth or adhesions.
Edema of the ventral body wall was observed in 7/20
SCID mice from Group RMK. Edema was not observed in mice
from any other groups. Edema in subcutaneous tissues and
muscle was primarily observed in the ventral abdominal
wall, but in some animals edema of the ventral neck,
thoracic wall, and/or rear limbs was also observed.
Lesions in the Thoracic Cavity
Enlarged mediastinal lymph nodes were frequently
observed in mice from 4 of the 5 test groups. Incidences
of 9, 9, 11, and 12/20 mice were observed for Groups RMK,
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3C9, 3D6, and 2B11, respectively. No mediastinal lymph
node enlargement was observed in mice from Group 2C6D9.
Enlarged lymph nodes were characterized as single to
multiple, tan to white nodes located in the mediastinum at
the base of the heart, near the tracheal bifurcation.
Enlarged lymph nodes ranged in size from approximately 0.2
to 0.3 cm3 .
Mediastinal masses were observed in 3 SCID mice from
Group RMK and 1 CAF1 mouse from Group 3C9. Mediastinal
masses were not observed in mice from other groups. Masses
were red to tan-white in color, and were located in the
cranial mediastinum or at the base of the heart. Heart
base masses measured approximately 0.4 x 0.3 x 0.2 cm, and
one of the mediastinal masses filled the entire cranial
mediastinum. Microscopic examination of selected tissues
performed to define the mediastinal lymph node enlargement
and mediastinal masses demonstrated accumulations of tumor
cells within mediastinal lymph nodes.
Lesions at the Injection Site
Gross lesions were observed at the site of pristane and
hybridoma cell injection in mice from all test groups. The
injection site, which was the same for all mice in all
groups, was the left caudal, ventrolateral abdominal wall.
Subcutaneous and abdominal wall masses were observed
most frequently in Group 3C9 with incidences of 10/20 and
10/20. Five mice in this group had both subcutaneous and
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abdominal wall masses. Incidences of these lesions ranged
from 0-4/20 in mice from other test groups. Subcutaneous
and intramuscular masses within the abdominal wall were
reddish to tan, soft tissue masses ranging in size from
approximately 0.2 cm3 to 0.6 x 0.6 x 0.3 cm.
Masses within the abdominal cavity and attached to the
peritoneum at the injection site were observed in mice from
3 test groups. Incidences were 1, 2, and 3/20 for Groups
3C9, RMK, and 2B11, respectively. Peritoneal masses were
reddish, soft tissue masses ranging in size from 0.3 x 0.2
x 0.1 cm to 0.6 x 0.6 x 0.1 cm.
Microscopic examination of selected tissues performed
to define the injection site masses demonstrated that the
masses were tumors.
Lesions at the Abdominal Tap Site
Gross lesions were observed at the site of paracentesis
for collection of ascites in mice from all test groups.
The abdominal tap site, which was identical for all mice in
all groups, was the left midlateral abdominal wall.
Subcutaneous hemorrhage was very frequently observed at
the tap site for mice in all test groups with incidences
ranging from 16-20/20. Muscle hemorrhage was observed less
frequently, with incidences ranging from 2-3/20 for mice in
Groups 2B11, 2C6D9, and 3D6.
Subcutaneous soft tissue masses were observed at the
abdominal tap site in 12/20 SCID mice from Group RMK.
108
Similar lesions were not observed in other groups. These
subcutaneous lesions were characterized by raised, tan to
white soft tissue observed between the skin and abdominal
wall at the tap site, ranging in size from 0.2 to 1.0 cm2
in diameter. Microscopic examination of these lesions
demonstrated that the tissue was composed of hybridoma
tumor cells.
Edema was observed in the subcutaneous tissues and
muscle of the abdominal wall at the tap site in 4/20 SCID
mice from Group RMK. Edema was not observed at the
abdominal tap site in mice from any other groups.
No significant gross lesions were observed at necropsy
in any CAF1. or SCID control mice.
Necropsy Observations for Selected Animals
One mouse from Group 2B11 was euthanized on day 9 prior
to abdominal paracentesis. At necropsy, there was
hepatomegaly and bilateral renomegaly. Abdominal adhesions
were observed between the liver, stomach, and jejunum, and
there were many adhesions between pelvic structures. The
intestinal tract was generally devoid of ingesta. There
was right hydroureter, and a soft tissue mass was observed
at the neck of the bladder. The bladder wall was thickened
and reddened on cross-section, suggesting the presence of
an intramural mass within the bladder wall. Microscopic
examination of tissues from this mouse confirmed that the
urinary bladder wall was diffusely invaded by tumor
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resulting in destruction of the normal architecture of the
bladder wall and occlusion of the lumen of the bladder.
Tumor was also identified in accessory sex glands,
abdominal lymph nodes, mesenteric fat, kidney, and
diaphragm.
One mouse from Group 2C6D9 was found dead on day 11
prior to abdominal paracentesis. Hepatomegaly was noted
and there were abdominal adhesions present between the
small intestine and colon. The bladder was reddened and
distended, and there was an irregular reddened soft tissue
mass at the neck of the bladder. The bladder wall was
thickened and reddened on cross-section, suggesting the
presence of an intramural mass within the bladder wall.
Autolysis precluded histologic evaluation of tissues.
Two mice in Group 3C9 remained clinically normal and
produced no ascites during the study. Lesions observed at
necropsy for one mouse included a 1.8 x 1.0 x 0.7 cm thin-
walled, translucent cystic mass in the left caudolateral
abdomen, attached to the left peritesticular fat. There
was a 0.4 x 0.4 cm slightly raised, reddened mass within
the peritesticular fat and attached to the cystic mass.
There was also mild bilateral renomegaly.
The other mouse in Group 3C9 had a 1.8 x 0.8 x 0.7 cm
whitish-tan soft tissue mass in the mesentery of the
descending colon, and a segment of the proximal jejunum was
adhered to the surface of the mass. There was a reddened
soft tissue mass just caudal to the preceding mass, and
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also within the mesentery of the descending colon, with
dimensions of 0.5 x 0.5 x 0.3 cm. There was a small
reddened focus within the right peritesticular fat which
measured 0.2 x 0.1 cm in diameter. Hepatomegaly,
renomegaly, and splenomegaly were observed. There were
multiple white, raised plaques within the diaphragm 0.1 to
0.3 cm in diameter. In the thoracic cavity, there was a
white soft tissue mass at the base of the heart which
measured 0.4 x 0.4 x 0.2 cm.
ASCITES VOLUMES AND ANTIBODY QUANTITATION
Ascites volumes and antibody quantitation data are
presented in Table 6. Data are presented for taps 1, 2,
and 3, respectively, for each cell line. Ascites volumes
are post-centrifugation volumes.
Ascites Volumes
Different trends were observed between groups when mean
ascites volume/mouse obtained over time from taps 1 through
3 were compared. For Group 2B11, the mean volume/mouse
obtained at tap 1 (3.2 ml) was significantly greater than
mean volumes obtained at taps 2 and 3 (1.5 and 1.2 ml,
respectively). For Group RMK, mean volumes were
significantly greater at taps 1 and 3 (2.5 and 2.1 ml,
respectively) by comparison to tap 2 (1.2 ml). For Group
2C6D9, significant and progressive decreases in mean
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volumes were observed from tap 1 through 3 (2.6, 1.2, and
0.6 ml, respectively). No significant differences were
observed in mean volumes over time for Group 3C9 (2.0, 2.1,
and 1.6 ml, respectively) and Group 3D6 (2.1, 1.6, and 1.4
ml, respectively).
Antibody Concentration
Different trends were observed between groups in
comparison of antibody concentrations in ascites over time
from taps 1 through 3. For Groups 2B11 and RMK, there were
no significant differences in comparison of antibody
concentrations at taps 1 and 2, and the concentrations were
significantly greater at tap 3. Mean concentrations were
3.61, 4.32, and 6.36 mg/ml for Group 2B11 and 4.39, 5.69,
and 15.03 mg/ml for Group RMK for taps 1, 2 and 3,
respectively. The large standard deviation (+ 10.94 mg/ml)
in the mean antibody concentration for Group RMK at tap 3
reflects the variability in concentrations among individual
animals, inclusive of outliers with 0 and 44.45 mg/ml
antibody concentrations in ascites. For Group 3C9, the
mean concentration of antibody was significantly greater at
tap 2 (6.12 mg/ml) by comparison to taps 1 and 3 (2.50 and
3.84 mg/ml respectively). For Group 3D6, there was a
significant and progressive increase in mean antibody
concentration from tap 1 through 3 (3.83, 6.25, and 7.56
mg/ml, respectively). For Group 2C6D9, mean concentrations
at taps 2 and 3 (6.82 and 6.53 mg/ml, respectively) were
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significantly greater that the mean concentration at tap 1
(5.17 mg/ml).
Total Antibody Production and Mean Production Per Mouse
Total antibody production and mean antibody production
in mg/mouse for each tap reflect combined contributions of
ascites volumes and antibody concentrations. For Groups
2B11 and 2C6D9, antibody production was greatest at tap 1.
For Group 3C9, production was greatest at tap 2, and for
Group RMK, production was greatest at tap 3. For Group
3D6, production at taps 2 and 3 were not significantly
different, but production at tap 3 was significantly
greater than production at tap 1.
Total antibody produced was 454.50 mg for Group 2B11,
445.57 mg for Group 3C9, 422.90 mg for Group 2C6D9, and
489.36 mg for Group 3D6. The greatest production was
achieved in Group RMK where 996.64 mg of antibody was
produced.
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Ascites Volume Summary
Murine ascites volume summary data is presented in
Table 7. The mean volume per tap for taps 1, 2, and 3
combined, were similar among groups, ranging from 1.7 to
2.0 ml/tap. These data suggest that a correlation exists
between total ascites volumes and % of possible taps
performed. Group RMK which had 100% survival and 100% of
possible taps performed had the largest total volume of
ascites. Group 2C6D9, which had the lowest survival and
lowest % of possible taps performed (72%) also had the
lowest total volume of ascites.
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Table 7.
Murine Ascites
Volume Summary Data
cell
line
no. of taps
total
2B11
3C9
RMK
2C6D9
3D6
53
58
60
43
53
of taps'
88%
97%
100%
72%
88%
total vol
(ml)
107.7
109.5
115.7
74.2
x vol/tap
(ml)
2.0
1.9
1.9
1.7
90.3
1% = percentage of taps performed/possible maximum of 60.
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Another factor which impacted final ascites volumes was
the volume of the cell pellet which was discarded after
centrifugation of raw ascites samples. For taps 1, 2, and
3, the percentage of the total volume of ascites collected
which was discarded as cell pellets ranged from 20-26% for
Group 2C6D9, 13-16% for Group 2B11, 12-17% for Group 3C9,
12 to 14% for Group 3D6, and 7-8% for Group RMK. These
data relate to gross observations regarding the general
appearance of the ascites fluid. While there was
variability between animals and taps within groups, the
ascites obtained from mice in Group 2C6D9 was generally
very hemorrhagic. Ascites collected from mice in Group RMK
was generally clear. Ascites collected from other groups
was generally mildly to moderately hemorrhagic.
PRODUCTION TIME
Cumulative antibody production over time for all groups
of mice is presented in Figure 8. Day 0 was considered as
the day that the mice arrived at the animal facility,
therefore, production time is inclusive of the 6 day
quarantine period, the two weeks following injection of
pristane, and the time following hybridoma cell inoculation
and prior to abdominal taps. Production began for each
group at the time the first mouse was tapped.
Considerable variability between groups can be observed
in production time. Production was complete for Groups
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2B11 and 2C6D9 by day 35, while production for Group 3D6
was just beginning on day 35 and extended until day 51.
Production began for Group 3C9 on day 34 and was complete
on day 41. Production began on day 33 for Group RMK and
production was not complete until day 51. The relatively
flat slope of the production line for Group RMK from
approximately day 42 through day 51 indicates that mice
producing ascites late in time contributed relatively
little to the total production.
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PART 2: MONOCLONAL ANTIBODY PRODUCTION IN HOLLOW FIBER
BIOREACTORS
SYSTEM OPERATIONS
All systems were operated for 65 days without
contamination. Cell growth within the bioreactors was
monitored visually for systems A and B which had
transparent bioreactor cartridge shells. Visualization was
not possible for system C as the cartridge shell of the
hybrid reactor was opaque. Cells grew to confluency around
the bundle of hollow fibers and also settled in the gravity
dependent areas of the bioreactors.
The media contained phenol red as a pH indicator, and
by visual examination of the media color, pH gradients were
observed for all systems between the ICS media and the ECS
media. While the frequency of media changes in the ICS was
generally sufficient to maintain relative pH neutrality of
approximately 7.0 to 7.4, as determined by the red to
orange color of the media, the ECS media at the time of
product harvests was often visibly yellow indicating more
acidic pH of approximately 6.5. ECS harvests from the
hybrid reactors generally appeared less acidic than those
from the conventional bioreactors.
It was necessary to check tubing luer connections
frequently during the runs as they were observed to loosen
over time, presumably related to vibrations induced by the
media pumps.
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Technical difficulties were encountered in the
operation of all systems which required contact with
technical service representatives. These problems are
described below for the individual bioreactor runs.
System A
Cell Line 211
Cell viability dropped to 0% on day 46. Cells were
subsequently expanded in static culture for reinoculation,
and on day 53 the bioreactor was flushed and reinoculated
with 60 x 106 cells according to instructions provided by
the technical service representative. Operation of this
bioreactor was continued through day 91.
Cell Line RMK
No problems were encountered during this run.
Cell Line 3C9
On study day 49, small pieces of black debris were
observed in the media of the media bottle. Some debris was
aspirated from the bottle and examined microscopically.
The black debris ranged from approximately < 1 to 3 mm in
diameter and appeared amorphous with some linear strands.
The morphology was not suggestive of bacterial or fungal
contamination. Samples submitted for bacterial and fungal
cultures were negative.
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Black debris continued to be observed following media
bottle changes and pinpoint black solid debris was
subsequently observed on day 56 at the downstream potted
ends of some hollow fibers in the bioreactor. On day 58,
pinpoint black debris was also noted in some fibers at the
upstream potted ends. The impact of the apparent lodging
of debris in fibers on media flow rate, if any, is unknown.
No debris was observed in ECS samples.
After completion of the run and disassembly of the
system, a pipe cleaner was inserted into the metal tubing
of the media bottle cap assembly and black material was
removed from the inside of the metal tubing, suggesting
that something was leaching from the metal components of
the tubing. This possibility was subsequently confirmed in
discussions with the technical representative.
System B
In all system B runs, cloudiness was observed in the
ICS media which contained 1% serum. Media samples were
examined microscopically and were submitted for aerobic
bacterial and fungal cultures. No bacteria or fungi were
observed microscopically, and culture results were
negative. The technical representative stated that
cloudiness of the media was common and resulted from
denaturation of serum proteins caused by the media pump
mechanism.
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Cell Line 2B11
During the initial set up and media flush, the media
pump failed before the ECS of the bioreactor had completely
filled with media. The system was subsequently
disassembled and returned to the manufacturer. The pump
was repaired and the bioreactor cartridge was replaced by
the manufacturer.
The 65 day run was completed after the second system
set up. On day 25, media was observed leaking from a crack
in the plastic luer connector of one of the cartridge ECS
harvest ports. Parafilm was placed over the harvest port
luer plug and around the cartridge. Subsequent ECS
harvests were obtained from other harvest ports. The
parafilm stayed in place for the remainder of the run,
prohibited further leakage of media, and prevented
contamination of the system.
Cell Line 3C9
Thermoregulation problems with the CO2 incubator in
which the system was housed were first noted on day 51.
Alternative incubator space was not available for this
system, and attempts to repair the temperature sensor were
unsuccessful. Incubator temperature varied between 37.0
and 38.5°C during the remainder of the run. The mean
temperature during this period of time was 37.6°C.
On day 63, the CO2 tank step down regulator
malfunctioned and resultant pressure changes apparently
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caused disconnection of the gas tubing from the CO2 tank to
the incubator in which the system was housed. The CO2
measured inside the incubator at the time the malfunction
was discovered was 0%, and the color of the media was
slightly purple indicating that the pH had become basic in
the absence of CO2. The author had been working in the
laboratory that afternoon and became aware of the problem
when frost was noticed on the regulator, therefore the
problem was not present for an extended period of time.
The gas tubing was reconnected and the regulator was
replaced.
Cell Line RMK
No problems were encountered during this run.
System C
During system set up and media flush procedures, media
flow could not be established in one of the three
bioreactor circuits. All system components were thoroughly
examined in attempt to identify the source of the problem.
After ruling out malfunction of other components, and after
discussions with the technical service representative, the
bioreactor cartridge in the circuit was replaced. Media
flow was then successfully established in all circuits and
the media flush procedure was initiated.
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Cell Line 2B11
No problems were encountered during this run.
Cell Line 3C9
Cell viability dropped to 0% on day 16. Cells were
subsequently expanded in static culture for reinoculation,
and on day 23 the bioreactor was flushed and reinoculated
with 100 x 106 cells according to instructions provided by
the technical service representative. Operation of this
bioreactor was then continued through day 65.
Cell Line RMK
No problems were encountered during this run.
LIMITING DILUTIONS
The stability of each cell line was measured after
limiting dilution as the percent of clones which tested
positive for antibody secretion. Percent positive clones
from limiting dilution of cells retained from bioreactor
cell inoculums on day 0 were 93, 93, and 100% for cell
lines 2B11, 3C9, and RMK, respectively. Percent positive
clones from limiting dilution of cells retained from
bioreactor ECS harvests on day 60 were 100% for all cell
lines from all systems with the exception of cell line 3C9
from system C where no wells developed clones after
limiting dilution.
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HARVEST VOLUMES AND ANTIBODY QUANTITATION
Harvest volumes and antibody quantitation data are
presented in Table 8. Product harvests began on day 4 for
systems A and B so there were a total of 27 harvests over
the 65 day run. Product harvests began on day 7 for system
C so there were a total of 26 harvests over the 65 day run.
Fewer harvests were made for cell line 3C9 in system C. No
harvests were made between the time of bioreactor cell
death and the 7th day post reinoculation of cells (harvest
days 21, 2:3, 25, and 28).
Harvest Volumes
Harvest volumes presented in the table are post-
centrifugation volumes. Total harvest volumes were similar
for systems A and C which would be expected as the
bioreactors for these two systems had the same
extracapillary space volume (7 ml). The larger total
harvest volumes for system B, approximately double the
volume for systems A and C, reflects the larger
extracapillary space volume of the bioreactor in this
system (12 ml).
The similarities in mean volume per harvest for all
cell lines within system B, and for all cell lines within
system C, reflect the standardized harvest volumes for
simultaneous ECS harvest and fresh media flush of the
bioreactors. The greater variability in mean volumes per
harvest for cell lines in system A reflects the variability
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of the volume of media and suspended cells in the ECS of
the bioreactors. Harvests for this system were obtained by
first aspirating the media with cells from the ECS and then
refilling the ECS with fresh media.
Antibody Concentration and Total Antibody Production
Mean antibody concentrations for cell line 2B11 in the
three bioreactor systems ranged from 0.71 to 1.31 mg/ml,
with total antibody production ranging from 91.11 to 249.49
mg in 65 days. For cell line 2B11 in system A, which was
reinoculated with cells on day 53, an additional 42.79 mg
of antibody was produced between days 67 and 91 (data not
presented).
Mean antibody concentrations for cell line 3C9 in the
three bioreactor systems were greater than those for cell
line 2B11, ranging from 2.16 to 4.45 mg/ml. Total antibody
production was 236.60 mg for system A and 380.71 mg for
system C. System B had the greatest mean antibody
concentration and the greatest total harvest volume
resulting in significantly greater total production of
1076.26 mg of antibody in 65 days.
Mean antibody concentrations for cell line RMK varied
significantly between bioreactor systems. Systems A and C
had very high mean concentrations of 11.08 and 10.11 mg/ml,
respectively. Total antibody production was also very high
in these systems. System A produced 1228.44 mg and system
C produced 1286.92 mg of antibody in 65 days. By
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comparison, the mean concentration of antibody for system B
was much lower at 2.30 mg/ml as was total production at
553.81 mg.
Antibody Concentration and Antibody per Harvest
Mean antibody per harvest ranged from 3.37 mg to 49.50
mg among all the different cell lines and systems tested,
and followed the same trends as those for total antibody
production. Total antibody production and mean antibody
per harvest reflect combined contributions of harvest
volumes and antibody concentrations.
Antibody concentration and total antibody in bioreactor
harvests over time for the 65 day run for each cell line in
each system are presented in Figures 9 and 10. For cell
line 2B11, the trend in antibody concentrations over time
were similar among systems. Concentrations gradually
increased, plateaued, and then decreased over the 65 day
runs.
Greater fluctuations in antibody concentration, both
within and between systems were observed for cell line 3C9.
Concentrations for system B peaked early in the run,
decreased then stayed relatively constant in the middle of
the run, then declined at the end of the run.
Concentrations decreased early in the run for system C in
association with bioreactor cell death. After cartridge
reinoculation, concentrations increased and stayed
relatively constant for the duration of the run. No clear
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pattern could be discerned in antibody concentrations over
time for system A.
For cell line RMK, concentrations peaked early in the
run for systems A and C and stayed relatively constant
until the latter part of the run where greater fluctuations
were observed prior to decline in concentrations at the end
of the run. Concentrations were relatively constant
throughout the run for system B, and were consistently
lower than concentrations for the other 2 systems.
Peaks observed in fluctuating antibody concentrations
over time were frequently associated with Monday harvests
after the longer 3 day weekend time interval as compared to
the 2 day time interval between other weekday harvests.
Trends in total antibody per harvest over time were similar
to the trends described for antibody concentrations over
time.
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MEDIA CONSUMPTION
ICS Media Consumed
The total volume of ICS media used from initial system
set up and media flush procedures through the end of the 65
day runs is presented below. The milligram amount of
antibody produced per liter of media consumed is also
indicated for each run.
Cell Line
2B11
3C9
RMK
System
A
B
C
A
B
C
A
B
C
ICS Media (L) Mg Antibody/L Media
5.75 15.85
10.00 24.95
22.00 7.48
8.25
14.00
20.00
15.75
17.50
22.00
28.68
76.88
19.04
78.00
31.65
58.50
Mean media consumption for all cell lines in the 3
systems was 15 liters of media in 65 days. The mean
quantity of antibody produced per volume of media consumed
for all cell lines in the 3 systems was 37.89 mg/L.
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ECS Media Consumed
The total volume of ECS media used from initial system
set up and media flush procedures through the end of the 65
day runs was relatively insignificant by comparison to ICS
media consumption. The total volume of ECS media consumed
for system A ranged from 139.5 to 157.7 ml. The volumes of
ECS media consumed for systems B and C were 270 and 180 ml,
respectively, as these volumes were standardized. An
additional 60 ml of ECS media was used for the bioreactor
ECS flushes prior to reinoculation of cartridges for cell
line 2B11 in system A and cell line 3C9 in system C.
MEDIA GLUCOSE CONSUMPTION, CELL COUNTS, AND CELL VIABILITY
It is the opinion of the author that total cell counts
varied considerably dependent on how vigorously the ECS of
the bioreactors was flushed during sample harvests; more
vigorous flushes yielded more cells. ECS harvests were
performed less vigorously early in the runs before the
bioreactors reached cell confluency, and were more vigorous
in mid to late parts of the runs in an attempt to prevent
overgrowth of cells in the bioreactors.
Mean values for total cell counts (x 106/ml), % viable
cells, and glucose consumption (mg/day) for the 65 day runs
for each cell line in the 3 bioreactor systems were as
follows:
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Cell Line System
2B11 A
B
C
3C9
Total
9.
21.
18.
A
B
C
RMK A
B
C
Cells % Viable
06 31
23 42
41 53
20.76
20.09
9.79
16.40
9.89
14.40
40
43
20
45
47
49
For cell line 2B11 in system A and cell line 3C9 in
system C, in which bioreactor cell death occurred during
the runs, mean cell viability was lowest. Mean cell
viability and glucose consumption were very similar in all
systems for cell line RMK. Greater variability in these
measurements was observed among systems for the other 2
cell lines.
Bioreactor antibody concentration in relation to media
glucose consumption, cell counts, and cell viability over
time are presented for each cell line in each system in
Figures 11 through 19. Changes in media serum
concentration over time are also indicated.
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Glucose
133
353
479
269
455
353
552
566
564
Cell Line 2B11
System A
The trends in glucose consumption and antibody
concentration over time were similar. Glucose consumption
decreased at the midpoint of the run prior to decreases in
cell viability and antibody concentration. Bioreactor cell
death as indicated by decrease in cell viability to 0%, was
associated with decreased glucose consumption and decrease
in antibody concentration. A significant increase in total
cell counts was observed on day 49. Glucose consumption
began to increase following reinoculation of cells on day
53. Because of relatively low glucose consumption and cell
viability during this run, 1% serum was maintained in the
ICS media and 10% serum was maintained in the ECS media
throughout the run.
System B
Considerable fluctuation in glucose consumption and
antibody concentration were observed over time. A decrease
in glucose consumption and cell viability was observed
between days 35 and 39. Following serum reduction in the
ICS media on day 51, there was a gradual decrease in
glucose consumption and total cell counts, and a transient
increase followed by decrease in antibody concentration.
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System C
Large fluctuations in glucose consumption were observed
over time, although the overall trend followed that of
antibody concentration. Reduction of serum in the ECS
media on day 42 was associated with a subsequent decrease
in antibody concentration. Antibody concentration
continued to decrease following increase in serum in the
ECS on day 56.
Cell Line 3C9
System A
The trends in glucose consumption and antibody
concentration over time were similar. These measurements
showed gradual fluctuations, increasing and decreasing over
time. Glucose consumption decreased and total cell counts
increased following serum reduction in the ICS media on day
44. Replacement of serum in the ICS media on day 53 was
associated with a subsequent increase in glucose
consumption. Antibody concentration decreased from day 51
through the end of the run.
System B
The trends in glucose consumption and antibody
concentration over time were similar. Antibody
concentration and glucose consumption peaked early in the
run on days 14 and 16, respectively, and then decreased
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gradually over the remainder of the run. Serum was removed
from the ICS media on day 11 and reduced in the ECS media
on day 49.
System C
Glucose consumption increased rapidly and then
decreased rapidly at the beginning of the run. Decrease in
glucose consumption and antibody concentration were
associated with bioreactor cell death as indicated by cell
viability decreasing to 0%. Following reinoculation of
cells on day 23 glucose consumption gradually increased,
and then decreased markedly following reduction of serum in
the ICS on day 46. Antibody concentration remained
relatively constant following reinoculation of cells.
Cell Line RMK
System A
The trends in glucose consumption and antibody
concentration over time were similar. Glucose consumption
and antibody concentration increased rapidly at the
beginning of the run. Serum was removed from the ICS media
on day 14. Following serum reduction in the ECS media on
day 23, glucose consumption gradually decreased, but there
was little change in antibody concentration. Following
increase in serum in the ECS media on day 35, glucose
consumption increased. Subsequent reduction of serum in
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the ECS media on day 39 was again associated with a
decrease in glucose consumption. Antibody concentration,
with some fluctuations, remained high until the end of the
65 day run.
System B
Glucose consumption increased rapidly early in the run
and then decreased following serum reduction in the ECS
media on day 11. Glucose consumption decreased transiently
then increased following increase of serum in the ECS media
on day 18. A decrease in glucose consumption was again
observed following decrease in serum in the ECS media on
day 46. Antibody concentration remained relatively
constant throughout the run, as did total cell counts.
System C
Large fluctuations in glucose consumption were observed
over time, although the overall trend followed that of
antibody concentration. Glucose consumption and antibody
concentration increased rapidly early in the run. A marked
decrease in glucose consumption and cell viability were
observed following removal of serum from the ICS media on
day 14, while antibody concentration remained relatively
constant. Glucose consumption and cell viability increased
following replacement of serum in the ICS media on day 21.
Subsequent lesser reductions of serum in the ICS media were
not associated with decreased glucose consumption.
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Figure 11.
Bioreactor Antibody Concentration, Glucose
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Bioreactor Antibody Concentration, Glucose
Consumption, Cell Counts, and Cell Viability
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Bioreactor Antibody Concentration, Glucose
Consumption, Cell Counts, and Cell Viability
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Figure 14.
Bioreactor Antibody Concentration, Glucose
Consumption, Cell Counts, and Cell Viability
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Figure 15.
Bioreactor Antibody Concentration, Glucose
Consumption, Cell Counts, and Cell Viability
Cell Line 3C9 - System B
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Figure 16.
Bioreactor Antibody Concentration, Glucose
Consumption, Cell Counts, and Cell Viability
Cell Line 3C9 - System C
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Figure 17.
Bioreactor Antibody Concentration, Glucose
Consumption, Cell Counts, and Cell Viability
Cell Line RMK - System A
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Figure 18.
Bioreactor Antibody Concentration, Glucose
Consumption, Cell Counts, and Cell Viability
Cell Line RMK - System B
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Bioreactor Antibody Concentration, Glucose
Consumption, Cell Counts, and Cell Viability
Cell Line RMK - System C
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COMPARISON OF GLUCOMETER AND TEST KIT GLUCOSE MEASUREMENTS
Agreement between glucose measurements made using the
glucometer and the Sigma glucose test kit, as determined by
Pearson's correlation coefficient, was 0.982. The
coefficient of variation was 6.2%. The difference in the
means demonstrated a +18 mg/dl bias for measurements made
using the glucometer. Results obtained using the method of
Bland and Altman (91) suggested that the limits of
agreement between the two methods could vary by as much as
+61.8 to -25.8 mg/dl within a 95% confidence interval.
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PART 3: COMPARISON OF MONOCLONAL ANTIBODY PRODUCTION IN
MURINE ASCITES AND HOLLOW FIBER BIOREACTORS
EQUIPMENT AND MATERIALS REQUIRED
Much of the equipment and materials requirements for
producing monoclonal antibodies do not differ for
production in mice and bioreactors. Equipment and
materials in common include a cell culture laboratory, CO2
incubator, hybridomas, cell culture media, water bath, cell
culture plasticware, pipets and centrifuge tubes, needles
and syringes, biological safety cabinet, microscope,
hemocytometer, centrifuge, and autoclave. There are
significant. differences in the time usage and quantity of
some of the equipment and materials used. For example,
cell culture equipment and materials are used for only a
short time as necessary to expand hybridomas for injection
into mice, whereas CO2 incubator space requirements and
cell culture material requirements are much greater for the
bi oreactors.
Equipment and materials specific to production in mice
include mice, pristane, and an animal facility and staff.
Equipment and materials specific to production in the
bioreactors include the bioreactor systems and a glucometer
with test strips for measurement of media glucose.
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TECHNICAL EXPERTISE REQUIRED
Technical expertise required for monoclonal antibody
production in mice includes growing hybridomas in culture,
and performing intraperitoneal injections and abdominal
paracentesis. The ability to make accurate clinical
assessments of the condition of the animals is also
necessary to minimize morbidity and mortality.
Technical expertise required for monoclonal antibody
production in bioreactors includes growing hybridomas in
culture, operation of bioreactor systems, and measurement
of media glucose. Measurement of media glucose with the
glucometer was a very simple technique. It is the opinion
of the author that the degree of technical expertise
required to successfully operate the bioreactor systems
without contamination over a period of 65 days is
significantly greater than the technical expertise required
to perform procedures with the mice. It is also the
opinion of the author that more time is required to develop
technical expertise in the operation of bioreactor systems
than that required to develop expertise in performance of
procedures with mice. The background and technical
experience of the individual would need to be taken into
consideration with regard to development of technical
expertise specific to manipulations with mice or
bi oreactors.
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MATERIALS COSTS
Costs for materials used in monoclonal antibody
production in mice and bioreactors are presented in Tables
9 and 10. Material costs are for antibody production in
groups of 20 mice, and for bioreactor systems operation for
65 days.
Material costs for antibody production in
immunodeficient SCID mice were significantly greater than
for production in conventional CAF1 mice. These costs
reflect the higher purchase price for SCID mice and higher
per diem for maintenance and husbandry for these mice under
aseptic conditions. It should be noted that the per diem
cost for SCID mice is inclusive of all disposable garments
such as surgical masks and bonnets, lab coats, and shoe
covers which were worn each time the animal room was
entered.
Material costs for monoclonal antibody production in
hollow fiber bioreactors are presented in Table 10. Total
material costs for all 3 systems, exclusive of capital
costs for bioreactor system instrumentation and the
glucometer, were higher than total material costs for
antibody production in CAF1 mice, but lower than material
costs for antibody production in SCID mice. Actual total
material costs for production in the bioreactors would be
dependent on the method used to amortize capital costs.
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Table 9.
MAb Production in Murine Ascites
Material Costs
Group
2B11 3C9 RMK
Purchase/Shipping
Groups 2B11 and 3C9
20 CAF1/J 7-wk male mice @ 7.50 $ 150.00
Shipping charge & processing fee 41.50
Group RMK
20 C.B.-17/1cr Tac-scid DF
7-wk male mice @ 27.00 540.00
Shipping charge & processing fee 49.00
Per Diem Fees
5 cages, 37 days @ 0.402 per diem/cage
5 cages, 41 days @ 0.402 per diem/cage
5 cages, 51 days @ 1.070 per diem/cage
Pristane Priming
Cost includes pristane, sterile
needles and syringes, alcohol prep
pads, and latex gloves
Hybridoma Inoculation
Cells: 1x106 cells/mousex20 = 20x10 6 cells.
Cost includes media for cell expansion and
animal inoculation, cell culture plasticware,
pipettes, centrifuge tubes, sterile needles and
syringes, alcohol prep pads and latex
gloves
Abdominal Tap
Cost includes sterile needles and syringes,
alcohol prep pads, latex gloves, centrifuge
tubes, and Pasteur pipettes
53 taps @ 0.41 /tap
58 taps @ 0.41 /tap
60 taps @ 0.41 /tap (plus sterile gloves)
Total Material Costs $
Costs reflect MIT DCM actual costs.
nci = no cost included
Suppliers Baxter Inc: Needles, syringes, alcohol prep pads
MIT Lab Supplies: Cell culture plasticware
Sigma Chemical Co: Pristane
Henry Schein Inc: Sterile latex gloves
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191.50
74.37
4.31
nci
5.95
21.73
297.86
191.50
82.41
4.31
nci
5.95
23.78
307.95
589.00
272.85
4.31
nci
5.95
35.82
907.93
Table 10.
MAb Production in Hollow Fiber Bioreactors
Material Costs
System
A B C
System setup: Cost for sterile latex gloves
ECS media flush: including pipettes,
centrifuge tubes, needles, syringes,
alcohol prep pads, and latex gloves
Hybridoma Inoculation
Cells: 60x10 6 - 103x10 6 /bioreactor
Cost includes media, cell culture
plasticware, pipettes, centrifuge tubes,
syringes, alcohol prep pads, and latex
gloves for cell expansion, preparation
and inoculation
ECS and ICS sample collections: including
pipettes, centrifuge tubes, needles, syringes,
alcohol prep pads and latex gloves
Cell counts and glucose tests: including
eppendorf tubes, pipettes, and glucose
test strips
ECS and ICS media and preparation:
including media & pipettes for addition
of supplements
CO2 tank
Bioreactor Cartridge (1)
Subtotal for operations $
Additional costs for problems discussed in text
Total for operations $
Capital costs:
System A (including 4 bioreactor cartridges)
Systems B & C (no cartridges included)
Glucometer
Total for capital costs $
0.66
1.71
nci
9.62
39.96
41.16
115.98
4.67
250.00
463.76
4.23
467.99
4,950.00
62.99
5,012.99
0.66
1.71
nci
13.00
41.85
41.16
115.40
7.00
115.00
375.78
5.22
381.00
4,000.00
62.99
4,062.99
0.66
2.11
nci
9.62
48.62
41.16
248.60
4.67
195.00
550.44
3.56
554.00
7,235.00
62.99
7,297.99
Costs reflect MIT DCM actual costs per bioreactor, averaged for the 3 runs in each system.
nci = no cost included
Suppliers Baxter Inc: Needles, syringes, alcohol prep pads
MIT Lab Supplies: Cell culture plasticware
BioWhittaker Inc: Cell culture media and supplements
Henry Schein Inc: Sterile latex gloves
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TIME SPENT IN LABOR
Time spent in labor for monoclonal antibody production
in mice and hollow fiber bioreactors is presented in Tables
11 and 12. Labor time is for antibody production in groups
of 20 mice, and for bioreactor systems operation for 65
days.
Total labor time was similar for all groups of mice.
The smallest labor time was for Group 2B11 where the
development of ascites, and consequently abdominal tap
times were relatively synchronous among animals in the
group. This group also had the shortest duration of time
for completion of all abdominal taps. The largest labor
time was for Group RMK where there was greater variability
in the development of ascites, and consequently abdominal
tap times among animals in the group. This group also had
the longest duration of time for completion of all
abdominal taps. Additional time was also required for
donning appropriate garb and performance of techniques to
assure maintenance of asepsis when handling these animals.
Time spent in labor for monoclonal antibody production
in hollow fiber bioreactors is presented in Table 12.
Total labor time was relatively similar for all systems.
Greater total labor time for system B reflects greater time
for preparation of the system for autoclaving, system set
up and media flush procedures, and media bottle changes.
Operational methodology for performing media changes was
more time consuming for this system as compared to the
155
others.
Overall, the time spent in labor for operation of
bioreactor systems was approximately double the amount of
time spent in labor for the mice.
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Table 11.
MAb Production in Murine Ascites
Labor Time
Group
Pristane Injection
Hybridoma Cell Expansion
> 20 x 106 cells
Preparation of Hybridoma
Inoculum
Hybridoma Inoculation
Daily clinical observations,
abdominal taps, and
euthanasia
Total Time
Times not included: preparation of the animal protocol for IACUC submission, ordering
animals, uncrating animals at receipt, walking to and from the animal facility, centrifugation
and processing of ascites, record keeping, disposal of animal carcasses.
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2B1 1
20 min
30 min
30 min
20 min
6 hr 9 min
7 hr 49 min
3C9
23 min
30 min
30 min
20 min
6hr 56 min
8 hr 40 min
RMK
27 min
30 min
30 min
25 min
7hr 8 min
9 hr 0 min
Table 12.
MAb Production in Hollow Fiber Bioreactors
Labor Time
System
Preparation of unit for
autoclaving
Preparation of media bottles
and cap assemblies for
autoclaving
Preparation of extra
luer plugs for autoclaving
Media preparation with
supplements
System set up & media flush
Check for sterility, check
connections
Hybridoma cell expansion:
Systems A, C >60 x 106 cells
System B >103 x 106 cells
Preparation of hybridoma
inoculum
ECS media flush and cell
inoculation
E(S and ICS sample
collections
Media bottle changes
Cell counts and glucose tests
Change injection septa on ports
Media bottle & cap assembly
cleaning and preparation
for autoclaving
Subtotal
Additional problems as dis-
cussed in text
Total Time
A
0 min
10 min
10 min
45 min
20 min
5 min
40 min
35 min
20 min
7 hr 12 min
1 hr 10 min
4 hr 30 min
0 min
15 hr 57 min
45 min
16 hr 42 min
B
30 min
10 min
10 min
1 hr 0 min
*lhr 37 min
5 min
50
40
min
min
35 min
7 hr 12 min
3 hr 7 min
4 hr 30 min
1 hr 33 min
21 hr 59
1 hr 23
23 hr 22
min
min
min
C
0 min
15 min
0 min
1 hr 5 min
38 min
5 min
40 min
35 min
35 min
6 hr 56 min
1 hr 43
4 hr 20
20
52
min
min
min
min
18 hr 4 min
1 hr 17 min
19 hr 21 min
* 'Takes -40 min for cartridge ECS to fill.
Times indicated for each system are times per bioreactor,
runs in each system.
which were averaged for the 3
Times not included: cleaning incubator, measuring incubator CO02, changing C02 tanks, filling
incubator water pan, conversations with technical representatives, returning
instrumentation for repairs, time to warm media before use, tracking media and supplement
stocks, ordering, walking to and from autoclave, centrifugation and processing of ECS
samples, record keeping, making cell count and glucose consumption calculations.
158
I
SUMMARY: MONOCLONAL ANTIBODY PRODUCTION IN MICE AND
BIOREACTORS
Ascites and bioreactor harvest volumes, mean antibody
concentrations, mean antibody per harvest or tap, and total
antibody produced are presented for mice and bioreactors in
Table 13. The total volume of product for all cell lines
was similar for the mice and systems A and C, which had the
smaller bioreactor ECS volume. The total volume of product
for all cell lines was greater for system B, which had the
larger bioreactor ECS volume.
For cell line 2B11, the mean concentration of antibody
in ascites was significantly greater than the mean
concentration of antibody produced by any of the 3
bioreactor systems. Total antibody production in 20 mice
was also significantly greater than the total antibody
produced by any of the 3 bioreactor systems in 65 days.
For cell line 3C9, the mean concentration of antibody
for system B exceeded the mean concentration in ascites.
Total antibody produced by system B in 65 days was more
than double the amount of antibody produced in 20 mice.
Mean antibody concentrations and total antibody production
for systems A and C were less than those for the mice, but
both concentrations and total production were greater than
those achieved for cell line 2B11.
For cell line RMK, the mean concentration of antibody
for systems A and C exceeded the mean concentration in
ascites. Total antibody production for both these systems
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also exceeded the total antibody produced in 20 mice. The
mean concentration of antibody for system B was
significantly lower than that for the other bioreactor
systems and ascites. Total antibody production for system
B was less than half that produced by systems A and C.
Overall, antibody production in mice and bioreactors was
greater for cell line RMK as compared to other cell lines.
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PRODUCTION TIME
Cumulative antibody production for each cell line over
time is presented for mice and bioreactor systems in Figure
20. Day 0 for the mice was defined as the day that the
animals arrived at the animal facility. Day 0 for the
bioreactor systems was defined as the day of system set up.
For cell line 2B11, it is clear that a significantly
greater amount of antibody was produced in murine ascites
in a shorter period of time by comparison to any of the 3
bioreactor systems.
For cell line 3C9, system B produced a greater amount
of antibody in a shorter period of time by comparison to
production in the other bioreactor systems and mice.
Greater antibody production was achieved in murine ascites
in a shorter period of time by comparison to production for
systems A and C.
For cell line RMK, production was achieved earlier for
systems A and C. Production in these 2 systems and murine
ascites reached near equivalence at approximately day 39;
bioreactor production exceeded production in mice by day
66. Less antibody was produced over time for system B as
compared to the other bioreactor systems and mice.
Because of the time associated with quarantine of the
animals, the time between pristane and hybridoma injection,
and the time between hybridoma injection and the first
abdominal taps for the mice when the antibody product was
first obtained, earlier initiation of antibody production
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for all cell lines was achieved by the bioreactor systems
in comparison to the mice.
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Figure 20.
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BIOREACTOR ANTIBODY PRODUCTION IN MOUSE EQUIVALENTS
Bioreactor antibody production in mouse equivalents is
presented in Table 14. For each cell line, antibody
production in the mice in mg/mouse was determined by taking
the total amount of antibody produced and dividing by 20,
which was the number of mice used in each group. These
figures were then used to calculate mouse equivalents based
on bioreactor antibody production for each cell line in
each system . There was great variability both within and
between cell lines when comparing mouse equivalents for the
bioreactor systems. For cell line 2B11, in which
bioreactor antibody production was lowest, the antibody
produced in each of the 3 bioreactor systems was equivalent
to the use of from 4 to 11 mice. For cell line 3C9,
antibody production in the bioreactor systems ranged from
10 to 48 mouse equivalents. For cell line RMK, antibody
production in the bioreactor systems ranged from 11 to 27
mouse equivalents.
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Table 14.
Summary Data
Bioreactor Antibody Production in Mouse Equivalents
bioreactor
system
total Ab
(mg)
mouse
equivalents
2B11
22.73 mg
Ab/mouse
3C9
22.28 mg
Ab/mouse
RMK
48.33 mg
Ab/mouse
System A
System B
System C
System A
System B
System C
System A
System B
System C
cell
line
91.11
249.49
164.46
4
11
7
236.60
1076.26
380.71
10
48
17
1228.44
553.81
1286.92
25
11
27
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SECTION 6: DISCUSSION
Results of clinical observations, body weight
measurements, and necropsy observations demonstrate
significant clinicopathologic changes in mice associated
with monoclonal antibody production via growth of ascitic
tumors. A variety of pathologic processes were identified
in association with different aspects of the production
technique.
During the two weeks following injection of pristane
and prior to inoculation of hybridoma cells, no clinical
abnormalities were observed in any mice. Additionally, no
significant differences in body weights were observed
between test and control animals during this period. These
findings suggest that the injection of 0.5 ml pristane
intraperitoneally does not cause clinically detectable
morbidity. However, as body weight measurements were
recorded once weekly during this period, the possibility
that there could have been a decrease in body weights and
subsequent recovery within the first or second week
following pristane injection cannot be definitively ruled
out.
On day 0, prior to hybridoma cell inoculation,
subcutaneous nodules were observed in some animals at the
site of pristane injection. These nodules decreased in
size or became clinically inapparent over time in greater
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than half of the animals which demonstrated this lesion.
Based on observations of the granulomatous inflammation in
the peritoneum induced by pristane (6,63), it is suspected
that these subcutaneous lesions were granulomas induced by
a small amount of pristane which, particularly due to its
high viscosity, may have been deposited at a subcutaneous
site along the needle track during intraperitoneal
injections. Subsequent resolution of the granulomatous
inflammation over time may have accounted for the reduction
in size of these lesions in some animals. The incidence of
this lesion in this study was 8/100 mice or 8%. Histologic
examination of these lesions would be required for
confirmation.
Subcutaneous nodules were also observed in some animals
at the site of intraperitoneal injection following the
inoculation of hybridoma cells. The nodules increased in
size over time in greater than half of the animals in which
the lesion was observed. Histologic examination of these
nodules demonstrated subcutaneous foci of tumor growth.
Increasing size of these tumors over time would not be
unexpected, and hybridomas have been previously reported to
grow in subcutaneous sites (2,15,16,18). As the necropsy
observations in the study suggest that the hybridoma cells
have a tropism for fat, it does not seem surprising that
subcutaneous tissues primarily composed of fat would
provide a satisfactory microenvironment for the growth of
these cells. Tumor growth within the abdominal wall at the
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injection site was also observed. These subcutaneous and
intramuscular sites of tumor growth likely resulted from
hybridoma cells which were deposited along the needle track
during intraperitoneal injections. At the time of necropsy
it was not possible to distinguish subcutaneous masses at
the injection site which arose before or after hybridoma
cell inoculation. However, fifty percent of the animals in
Group 3C9 had subcutaneous masses at necropsy which were
first observed during clinical observations 13 to 20 days
following hybridoma cell inoculation. Tumor growth was
also observed within the abdominal wall at the injection
site in fifty percent of the animals in this group. The
greater incidence of tumor growth in the subcutaneous
tissues and abdominal wall at the injection site in these
animals suggests that hybridoma cell line 3C9 may have a
greater propensity for growth in subcutaneous or
intramuscular sites.
In addition to subcutaneous and intramuscular growth of
tumor at the injection site, solid tumor masses were also
observed with greatest frequency in the left caudal
ventrolateral abdomen, and some tumors were attached to the
peritoneum at the injection site. These findings suggest
that initiation of solid tumor growth may begin locally, at
the site of hybridoma cell injection. It might be
interesting to investigate whether dividing the hybridoma
inoculum for administration in more than one site would
result in the growth of a larger number of smaller tumors
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instead of the relatively large solitary tumors most
frequently observed in this study. The potential benefit
to the mouse, if any, would also need to be determined.
Necropsy observations and histologic findings for the
two mice which died or were euthanized prior to development
of ascites and abdominal paracentesis, demonstrated the
presence of intramural tumor within the bladder wall.
Inadvertent injection of hybridoma cells into the wall of
the bladder could potentially account for the apparent
rapid infiltrative growth of tumor at this site.
Inaccurate injection technique, therefore, could be one
possible source of subsequent morbidity and mortality. The
incidence of this lesion was 2/100 mice or 2%.
The onset of clinical abnormalities such as roughened
haircoat and hunched posture were associated with the
initial development of ascites, and probably tumor growth,
as determined by the progressive increase in abdominal
distention and body weights. The mean percent increase in
body weights between day 0 and the before tap weights at
the first abdominal tap, for all groups of test mice
combined, was 17.4%. This figure correlates relatively
well with the recommendation in the UKCCCR guidelines (12)
which states that ascites volumes should not usually exceed
20% of normal body weight. The plateau in mean body
weights in the 1-2 days immediately preceding tap 1, as
illustrated graphically for Groups 2B11 and 2C6D9, suggests
that additional delay in the first abdominal paracentesis
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would not have resulted in collection of greater ascites
volumes. The plateau in body weights could indicate that
there is little further distensibility in the abdominal
wall, and consequently the pressure created by the large
volume of ascites may prohibit further ascites production.
The smallest mean percent increase in body weight from
day 0 to tap 1 (10.11%) was observed in Group 2C6D9.
Clinical abnormalities in this group were the most severe
and rapidly progressive, and mortality was greatest in this
group. This group was also was the first group tapped
following hybridoma
percent increase in
(23.77%) was observe
in this group were t
progressive, and 100
to the end of the st
range of days over w
performed (days 13 t
related to the obser
for these groups bet
inoculation (day 11). The largest mean
body weight from day 0 to tap 1
d in Group RMK. Clinical abnormalities
he least severe and most slowly
% of the animals in this group survived
udy. This group also had the largest
hich the first abdominal tap was
o 27). These factors are likely
ved percent increases in body weight
ween day 0 and the first tap.
Although there were significant differences between
groups, the general progression of clinical symptomatology
over time among groups was similar. The differences which
were observed between groups in the incidence, severity,
and rapidity of progression of clinical abnormalities
during the study did have significant impact on survival,
and ultimately, on the amount of antibody produced.
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The clinical abnormalities which appeared to have the
greatest impact on survival were those observed during the
time immediately following abdominal paracentesis. These
abnormalities included roughened haircoat, hunched posture,
decreased activity, increased respiratory rate and in some
cases dyspnea, and pallor. Control animals which received
sham paracentesis demonstrated none of these clinical
abnormalities. This observation would suggest that these
signs were associated with the removal of ascitic fluid,
rather than with stress resulting from restraint and the
paracentesis procedures.
The abnormal clinical signs observed following
paracentesis are compatible with signs of circulatory
shock. Rapid removal of ascitic fluid in humans has been
associated with hypotension (9), hypovolemia (9,10,13), and
protein depletion (13). Similar complications have been
observed in animals following removal of ascitic fluid
(14). In this study, these signs were most often transient
suggesting that the mice were able to compensate via
physiologic mechanisms which possibly included tachycardia
and peripheral vasoconstriction. The recommendation for
use of general anesthetics during abdominal paracentesis in
mice might be questioned in view of these findings, as many
general anesthetic agents cause myocardial depression (92)
and hypotension (93) and could potentially exacerbate any
existing cardiovascular deficits. Additionally, in human
and veterinary clinical practice, general anesthetics are
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not routinely employed for paracentesis, although local
anesthetic agents are sometimes used. Supportive therapy
such as supplemental oxygen or warm fluids for volume
expansion could be considered, but may be of questionable
practicality. The additional stress resulting from
administration of therapeutic agents would need to be
weighed in view of the potential benefit.
In examination of individual animal data, no definitive
correlation could be made between the magnitude of the
percent drop in body weight at the time of abdominal taps
and the presence or absence of clinical abnormalities
following paracentesis. However, these data have not yet
been subjected to rigorous statistical correlation
analyses.
It is important to note that all of the animals in this
study which died did so within approximately 30 minutes
following abdominal tap, with the exception of one animal
which died early in the study and was found to have a
bladder tumor. With the exception of one animal euthanized
early in the study with a bladder tumor, animals were
euthanized during this study because the clinical
abnormalities observed following abdominal paracentesis
were indicative of severe distress, or were persistent
rather than transient and of sufficient severity to suggest
that the animals might not survive to the next observation
period. These findings point to the need for careful
observation of animals for at least 30 minutes following
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abdominal paracentesis to permit identification of animals
with severe or persistent post-tap clinical abnormalities
which warrant humane euthanasia. Careful clinical
monitoring of these mice following abdominal paracentesis
and appropriate use of euthanasia were successful in
preventing mortality at other timepoints during this study,
and were essential for providing humane care for the
animals. It should also be noted that abdominal
paracentesis and clinical observations were performed as
necessary 7 days a week without regard for weekends or
holidays.
Overall survival to tap 3 for all groups combined was
79%, which is significantly higher than another report
which states that generally only 10-25% of animals survive
to the third tap (4). This information further supports
the value of careful clinical monitoring of the animals to
reduce mortality. Greater survival should also positively
impact antibody production, as results from this study
demonstrate a relationship between percentage of possible
taps performed and total ascites volumes.
Six animals out of 100 died during this study for an
overall mortality rate of 6%. In the individual groups,
mortality ranged from 0 to 25%. These findings suggest
that even with frequent and careful clinical observations,
some mortality may occur, and that significant differences
in mortality may be observed between different cell lines.
The most severe and rapidly progressive clinical
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abnormalities were observed in mice from Group 2C6D9.
Mortality was highest in this group and the largest number
of animals euthanized were from this group. The greatest
incidence of decreased activity and dehydration was
exhibited by animals from this group. The presence of
dehydration suggests that these animals may have stopped
drinking water. Clinical abnormalities were observed
earlier, abdominal taps were performed earlier, and the
duration of survival was shorter for mice in this group as
compared to mice in other groups. The ascites obtained
from animals in this group was generally very hemorrhagic.
Previous studies have demonstrated erosion of blood vessels
by invasive abdominal plasmacytomas which was associated
with hemoperitoneum (54,60). Gross necropsy observations
for animals in this group did not demonstrate pathology
significantly different from other groups. More complete
histologic examination of tissues from these animals might
provide more information regarding pathologic mechanisms.
If tumor invasion through the intestinal wall could be
demonstrated, for example, endotoxemia could be postulated
as potentially having contributed to the clinical
observations made in these animals. The available data
suggest that this hybridoma cell line produced pathology
which progressed rapidly enough to significantly affect
survival of the animals. One consideration for future use
of this cell line in mice would be to use a smaller cell
inoculum with the intent of trying to slow the progression
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of tumor pathology.
Clinical abnormalities in animals from Group RMK were
the least severe and most slowly progressive, and 100% of
the animals in this group survived to the end of the study.
The ascites collected from these animals was generally
clear, and hemoperitoneum was not observed at necropsy in
any animals from this group. It was the impression of the
author that a number of the animals in this group could
have been tapped at least one additional time without
unduly compromising their clinical condition. In addition
to maintenance of good clinical condition over time, these
animals had very high concentrations of antibody in ascites
from the third abdominal tap, and if concentrations
remained high for subsequent taps, considerably more
antibody might have been produced. Another important
observation related to the significantly higher
concentration of antibody in ascites from the third tap
from these animals, is that approximately 2/3 of the total
antibody produced by this group was obtained from ascites
from tap 3. These findings should be taken into
consideration by Institutional Animal Care and Use
Committees. If, for example, the number of abdominal taps
for these animals had been restricted to a single tap, 93
mice would have been needed to produce the equivalent
amount of antibody produced by 20 mice in 3 taps. Although
lot to lot variation in murine ascites production
parameters has been observed within cell lines (4), the
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potential usefulness of quantitating production by tap is
clearly apparent. Contrary to the example provided by
Group RMK, there might be cell lines in which production is
sufficiently greater at tap 1 or progression of pathology
is sufficiently rapid or severe to warrant euthanasia
following the first tap.
These results suggest that decisions on the limitation
of the number of abdominal taps performed would best be
made in view of the clinical condition of the mice and
antibody production parameters to include ascites volumes
and antibody concentration for taps over time. Based on
the clinical appearance of most animals by tap 3, it is the
author's opinion that as a general recommendation, three
abdominal taps should be considered as a maximum, but that
additional taps could be considered for cell lines with
clinical effects and production parameters similar to those
for Group RMK.
Results of clinical observations in this study also
demonstrate variability among individual animals within
groups, therefore, decisions regarding the number of
abdominal taps performed and time of euthanasia need to be
made for each individual animal based upon ongoing
assessment of clinical condition.
Gross lesions observed at necropsy clearly demonstrate
significant pathology in these mice associated with
monoclonal antibody production from ascitic tumors. All
mice had disseminated intraabdominal tumor and/or solid
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tumor masses. Abdominal adhesions were also commonly
observed.
Hemoperitoneum frequently observed in mice from all
groups except Group RMK could have been the result of
trauma associated with paracentesis or could reflect the
presence of hemorrhagic ascites associated with tumor
invasion of blood vessels. The presence of subcutaneous
tumor at the tap site of mice in Group RMK suggests that
tumor cells seeded in the subcutaneous tissues during
collection of ascites from the abdominal cavity. Although
this lesion was observed grossly only in mice from Group
RMK, more complete histologic examination of tap site
tissues from mice in all groups would be necessary to
confirm the restriction of this lesion to Group RMK. The
relationship, if any, between the presence of subcutaneous
tumor at the tap site and persistent leakage of ascites
from the tap site after paracentesis is unknown. Chronic
leakage of ascites from paracentesis sites has been
observed in people with cirrhosis following repeated
paracentesis (13). Leakage of ascites from the tap site
and dependent subcutaneous edema were only observed in SCID
mice. These findings may be related to a greater tendency
for the development of hypoproteinemia in these mice
resulting from the combination of normally lower serum
total protein related to agammaglobulinemia, and the loss
of large quantities of albumin in ascites. Albumin in
mouse ascites fluid has been reported to be between 1.1 and
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1.8 g/dl (81).
Histologic evaluation of enlarged mediastinal lymph
nodes revealed tumor cells within these nodes. Metastasis
of tumor cells from the abdominal cavity to the thoracic
lymph nodes, presumably via the lymphatics, has been
previously reported for plasmacytomas (54,60).
Gross necropsy observations for the two animals from
Group 3D6 which remained clinically normal throughout the
study, demonstrated that despite significant pathologic
changes in the abdomen and chest, animals can continue to
appear clinically normal. Development of nonsecreting
solid tumors rather than ascites tumors (62) and
descriptions of less than 100% development of ascites in
mice after injection of pristane and hybridoma cells (11)
have been described. The overall incidence of mice which
did not produce ascites was 2/100 or 2% for mice which
survived to the time of ascites development.
Overall, these data suggest that with ongoing ascites
production, repeated abdominal paracentesis, and
progressive tumor growth, the clinical condition of ascites
mice generally worsens over time. Despite progressive
tumor growth and ascites production, body weights of the
mice after the first abdominal tap generally decreased over
time suggesting a significant loss of normal body mass in
the face of increasing weight contribution by the tumor.
Group RMK was an exception in that body weights continued
to increase from taps 1 through 3, suggesting that the
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clinical condition and hence normal body mass of these mice
was maintained in the face of increasing weight
contribution by the tumor. In view of all of these
findings, it is clear that this is not a benign process,
and the author would have to assume that there must be
stress associated with this process.
Others have demonstrated significant differences in the
behavior of different cell lines in mice (4), and
differences between cell lines were observed in this study.
Our findings must be viewed in reference to the fact that
only 5 cell lines were evaluated in this study, and these
results likely do not encompass the range of biologic
behaviors possible among different hybridoma cell lines.
Differences observed between groups of CAF1 mice and the
SCID mice cannot be differentiated based on the origin of
the difference in the strain of mouse or origin of the
difference in the hybridoma cell line.
Subsequent clinicopathologic studies of ascites mice
should include assessments of hematologic and biochemical
parameters to better evaluate blood loss and organ function
over time. Measurement of blood pressure and hematologic
parameters prior to and following abdominal paracentesis
would be useful to define the pathophysiology of the
observed post-tap clinical abnormalities, and to determine
whether hypovolemia and hypotension develop following
abdominal tap. Measurement of protein in serum and ascites
over time would assist in identifying the potential
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contribution of hypoproteinemia in relation to persistent
leakage of ascites from the tap site and the development of
edema in SCID mice.
The concentration of the antibody product from the
hollow fiber bioreactor systems in this study compare
favorably to results obtained by others (42,46,47,48), and
overall, compare favorably to concentrations in mouse
ascites, particularly in view of the low concentrations
attained using alternative in vitro culture methodologies
(42,46,47).
Variation observed in antibody production between
systems and cell lines may be related to differences in
system components such as the molecular weight cut-off of
the bioreactor fibers, or operational parameters such as
media flow rates and volumes of media exchanged, as well as
differences in the requirements of different cell lines.
To test these possible influences, one would need to
perform multiple runs with a single cell line, changing one
variable at a time, for example, using different bioreactor
cartridges in sequential runs within the same system, or
using the same bioreactor cartridge and changing media flow
rate in sequential runs within the same system.
Antibody productivity has been demonstrated to be
higher in bioreactors with 30 or 70 kD MWCO as compared to
bioreactors with 10 kD MWCO (47). There is a trade-off to
be considered, however, as leakage of IgG product from the
ECS to the ICS was barely detectable for the 30 kD MWCO
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bioreactor but was substantial for the 70 kD MWCO
bioreactor (47). Improved production with larger MWCO
bioreactors may result from reduced resistance to media
flow (26) and/or enhanced diffusion of low molecular weight
growth inhibitors such as TGF31 which is produced by some
hybridoma cells (52), from the ECS to the ICS.
With the exception of cell line RMK, total antibody
production was less in system A as compared to other
systems. The bioreactor for system A had a larger MWCO of
50 kD by comparison to the other systems which had MWCO of
10 kD. Lower production could have resulted from some
leakage of antibody from the ECS to the ICS for cell line
3C9 which was an IgG producing hybridoma, but leakage of
the larger IgM antibody of cell line 2B11 would not be
expected. Antibody was not measured in the ICS media of
any systems in this study. Alternatively, growth factors
such as insulin and transferrin, with molecular weights of
approximately 6 and 78 kD, respectively, have been shown to
increase hybridoma cell growth in hollow fiber bioreactors
(94,95). Greater diffusion of these serum factors away
from the cells in the system A bioreactor with the larger
MWCO may also have contributed to the lower production
observed. Lastly, decreased frequency of media exchanges
during these runs based on glucose consumption may have
resulted in limitation of other essential nutrients such as
glutamine, which decomposes spontaneously over time at 37°C
(86,87) and was not measured in ICS samples in this study.
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Based on the larger ECS volume for growth of cells in
the bioreactor for system B, one might expect greater
antibody production in this system by comparison to the
others. This was true for cell lines 2B11 and 3C9, but for
cell line RMK, production was lowest in system B.
Obviously, factors other than cell space affect production.
The impact of the different method of gassing provided by
the hybrid reactor for system C cannot be differentiated
from other potential variables affecting production.
Antibody production for all systems was lowest for cell
line 2B11, which was the only IgM product evaluated in this
study. This data suggests that this cell line may not
adapt well to growth in hollow fiber systems, or
alternatively, it may indicate that media conditions,
bioreactors, and/or operational protocols were not
sufficiently optimized for successful cell growth and
antibody production for this cell line. The latter
explanation is more likely, as the author is aware that
this cell line has been grown successfully in large scale
hollow fiber bioreactor production systems. Anecdotal
reports, however, suggest that some hybridoma cell lines
will not grow in hollow fiber bioreactor systems.
To the extent possible, conditions were standardized in
this study for bioreactor system operations for all cell
lines. No attempts were made in this study to optimize
conditions for individual cell lines. There are many
operational variables which could be manipulated to include
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media constituents, media flow rates and incremental
changes in flow rate over time, volume of media exchanges,
and harvest frequencies. Any or all of these factors have
the potential to affect antibody production. Particularly
in view of the observation of grossly visible acidification
of the ECS media between harvests and the potential for
increasing concentrations of cell-secreted inhibitory
substances such as TGF31 over time within the ECS, more
frequent ECS harvests could potentially have significant
impact on total production. Operational changes such as
this also would affect time spent in labor and material
costs.
Decline in antibody production toward the end of the 65
day runs was observed for all cell lines in all systems.
More novel operational strategies for maintaining
production over long periods of time includes periodic
agitation and flushing of the bioreactor with the intent of
removing cells to prevent overgrowth of cells in the
bioreactor (26). As long as sterility is maintained, and
components are manufactured to provide sufficient
longevity, reuse of bioreactors may also be possible with
trypsinization to remove cells, followed by reinoculation
of cells. The author would also like to investigate the
effect of intermittent pulses of ECS media with higher
concentrations of serum to evaluate the potential for a
beneficial effect on maintenance of cell growth and
production over longer periods of time.
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Results from this study demonstrated excellent
stability of these cell lines in terms of continued
antibody secretion over time for the duration of study.
Cell line stability is an important factor in consideration
of longer continuous production times, but the problem of
decreasing stability over time might be overcome by
periodic flushes and reinoculation of the bioreactor.
Glucose consumption appeared to be a relatively good
measure of cellular activity in the bioreactors, but
changes in glucose consumption did not always correlate
well with changes in antibody concentration. These
findings suggest that antibody concentrations should be
monitored frequently during bioreactor runs, rather than
relying on indirect measurements. For systems B and C, ECS
harvests were obtained by simultaneous aspiration of ECS
media and infusion of fresh media. Consequently, the ECS
samples assayed for antibody concentration were actually
mixtures, which may have contributed to the variability in
some measurements over time. Peaks in antibody
concentration, often associated with Monday harvests after
the longer 3 day weekend time interval, also contributed to
fluctuations in antibody concentration over time.
Large fluctuations in glucose consumption over time
were also observed, particularly in system C. This may
have been related to the larger 2 liter media exchanges for
this system, potentially resulting in greater dilution of
beneficial cell secreted products. Although good
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correlation was demonstrated by Pearson's correlation
coefficient (0.982), results obtained using the method of
Bland and Altman (91) suggested that the limits of
agreement for glucose measurements between the glucometer
and the Sigma test kit could vary considerably. This
finding suggests another possible source for fluctuations
in glucose consumption.
Changes in serum concentration in the ICS and ECS had
variable impact on glucose consumption, antibody
concentration, and cell viability within different cell
lines and systems over time. Overall, decreases in glucose
consumption and cell viability appeared more frequently
following serum reductions than decreases in antibody
concentration. These findings again suggest the importance
of monitoring antibody concentration during the bioreactor
runs.
In comparison of antibody production in bioreactors and
mice, advantages and disadvantages are associated with each
method. Advantages for the bioreactors include the
potential for more rapid initiation of production, and
sustained production over longer periods of time. However,
larger total quantities of antibody were more often
produced in a shorter period of time by the mice. The
potential for contamination or mechanical failure of the
systems themselves or supporting systems such as the CO2
incubator, account for less absolute certainty in projected
production times. Lot to lot variability in mice may also
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create uncertainty in projected production times.
Bioreactors can be operated on a 3 day/week schedule.
It is the impression of the author that mice producing
ascites must be monitored at least once each and every day,
including weekends, and holidays.
An animal facility is not required for production of
antibody in hollow fiber bioreactors, however more
extensive use of a cell culture laboratory is required for
operating bioreactors.
It is the author's opinion that operation of
bioreactors requires greater technical expertise than that
necessary to perform procedures in mice. The author also
recognizes that this factor is dependent on the background
and experience of the technician. The author's extensive
background and experience with animals and previously
limited experience in cell culture may be a source of bias.
It might also be noted that in view of the limited previous
cell culture experience of the author, the author was able
to successfully operate these bioreactor systems.
Time spent in labor and equipment and material costs
were greater for operation of bioreactors. True equipment
costs however, would be dependent on the method of
amortization of capital costs for instrumentation. As
these small scale systems have only recently been
commercially introduced, the longevity of the
instrumentation has yet to be determined. It should also
be noted that time spent in labor and material costs were
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determined for antibody production in 20 mice and
bioreactor operation for 65 days, both of which are
somewhat arbitrary.
Some of the problems encountered in the operation of
these small scale bioreactor systems may be related to the
recent development of this technology. These problems did
impact labor time, and to a lesser extent material costs
for the bioreactors. Presumably as the technology advances
there will be improvements in both system components and
operational techniques as more experience is gained in the
use of these systems.
Results of this study suggest that the behavior of
different hybridoma cell lines will likely vary in both
mice and bioreactors necessitating flexibility and
modifications in procedural parameters for individual cell
lines in an effort to decrease animal distress and increase
antibody production. In view of the demonstrated
differences between cell lines, it is important to
acknowledge that the results of this comparative study are
based on evaluation of only 3 hybridoma cell lines.
In consideration of humane aspects, the author
considers production of monoclonal antibodies in hollow
fiber bioreactors to be more humane than production in
mice. It should be noted, however, that the production of
hybridoma cells still requires the use of mice, and serum
used in the cell culture media is also an animal product,
so the use of animals has not been completely eliminated by
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this technology. A greater number of hybridoma cell lines
need to be critically evaluated in hollow fiber bioreactors
to more fully assess the potential of these systems to
serve as alternatives for the reduction or replacement of
the use of mice for monoclonal antibody production.
Results of this study demonstrate significant
clinicopathologic changes in mice associated with
monoclonal antibody production in ascites. Every attempt
should be made to improve procedural protocols to maximize
production so that the smallest number of animals can be
used without compromising humane care. Further
investigations should be conducted to determine the optimal
time interval between pristane priming and subsequent
inoculation of hybridoma cells, as the recommendations in
the current literature are widely disparate.
As hybridomas obviously grow well and secrete large
amounts of antibody in the microenvironment of the
pristane-primed mouse peritoneal cavity, future studies
should be designed to identify the specific factors
involved in the enhancement of cell growth and secretion at
this site. These factors could be added to the cell space
of bioreactors, or alternatively, one could consider co-
cultivation of hybridoma cells with other cells, such as
fibroblasts, which secrete growth factors. It is the
author's belief that hollow fiber bioreactor technology
holds great potential promise for future applications.
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SECTION 7: CONCLUSIONS
Significant clinicopathologic changes in mice were
demonstrated in this study in association with monoclonal
antibody production via the induction of ascitic tumors.
Monoclonal antibodies from 3 cell lines were produced in 3
different, commercially available, laboratory scale hollow
fiber bioreactor systems. Results of this study suggest
that hollow fiber bioreactor systems merit further
investigation as viable alternatives to monoclonal antibody
production in murine ascites.
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